Podcasts about co inventor

With sign-stealing scandals shaking Major League Baseball, the game needed a solution. Enter PitchCom, the cutting-edge communication technology that's changing the way baseball is played.In this episode of The TechEd Podcast, host Matt Kirchner sits down with John Hankins, co-inventor and owner of PitchCom, to unpack the surprising origins of the technology (it was inspired by John's stage mentalism experience!), the innovative and unhackable tech that comprises the PitchCom system, and why it has completely changed the game of baseball. Beyond baseball, PitchCom is a case study in applied technology—how engineering, wireless communication, encryption, and even sound design can be used in unexpected ways. The lesson for educators? What your students learn in the technical education classroom—electronics, software, mechanics, and problem-solving—can lead to groundbreaking inventions in any arena.Listen to learn:How stage mentalism, sound engineering, and encryption tech came together to create PitchComHow PitchCom reduced wild pitches to the lowest levels in MLB history and sped up game play by cutting down time lost to sign-callingWhy PitchCom's encryption is so secure that it's mathematically impossible for teams to hack—more secure than the number of atoms in the universeHow engineering students can apply their skills in creative industries—from sports tech to entertainment and beyondWhy college baseball, the Canadian Football League, and even scuba diving are exploring this technologyWhat future inventors need to know about turning ideas into patented, market-ready productsIf you teach technical education or have students interested in technology, this episode is a must-listen. The next big innovation could come from your classroom!3 Big Takeaways from this Episode:1. Innovation thrives in times of urgency and challenge.PitchCom wasn't just a cool idea—it was a solution to a crisis in baseball. The Houston Astros' sign-stealing scandal created an undeniable need for secure communication, and John Hankins applied existing technology in a new way to fill that gap. Great inventions don't start with ideas—they start with problems.2. True innovation comes from blending different disciplines.John's background as an engineer, patent attorney, and stage mentalist gave him a unique perspective on communication and encryption. Whether it's combining sports and tech, or magic and engineering, the biggest breakthroughs come from crossing industry boundaries and thinking outside traditional silos.3. Data is the future of every industry.PitchCom started as a tool to prevent sign-stealing, but now it's unlocking new levels of player performance data—tracking pitch accuracy, command, and strategy in real time. From sports to manufacturing to education, those who understand and leverage real-time data insights will lead the future.Resources in this Episode:To learn more about PitchCom's technology, visit: pitchcom.comWe want to hear from you! Send us a text message.Instagram - Facebook - YouTube - TikTok - Twitter - LinkedIn

Join Mike Paciello, Chief Accessibility Officer at AudioEye, and Bryce Johnson, Principal Research Accessibility and Inclusive Design at Microsoft and Co-Inventor of the Xbox adaptive controller, in the latest episode of HearSay. Mike and Bryce discuss accessibility in online gaming and the incredible work that's gone into making the industry more accessible to individuals with disabilities. They also discuss how organizations can make their designs more inclusive using data and involving the disability community as much as possible.——View transcript: https://aeurl.xyz/hearsay-podcast-with-bryce-johnsonHearSay is produced by Sojin Rank, Mike Barton, Mariella Paulino, and Missy Jensen. Edited by Alex Dorrier.HearSay is a podcast focusing on the advocates, heroes, and leaders making the web more accessible. We're interviewing these change makers to hear what they have to say, to set the record straight, and offer their perspectives on how we can all work to make the web accessible to all.

Peter Voss is the visionary founder and CEO of Aigo.ai, a pioneering company at the forefront of conversational AI and natural language processing. Over the past 15 years, Peter and his team have perfected a highly intelligent, hyper-personalized chatbot designed for enterprise customers. In 2009, Peter founded SmartAction.ai, which developed the first AI-based contact center technology. Beyond his entrepreneurial endeavors, Peter is an engineer, inventor, and AI pioneer who writes and presents on philosophical topics such as rational ethics, free will, and artificial minds. He is also deeply involved in futurism and radical life extension.In this episode, we discuss:Peter Voss's Journey: From an electronics engineer to creating a successful software company, and his deep dive into the nature of intelligence and AI.Defining AGI: What Artificial General Intelligence (AGI) means to Peter, and how we will recognize its achievement.Cognitive Skills Gap: The differences between current AI technologies like large language models (LLMs) and true cognitive skills required for AGI.Path to AGI: The limitations of deep learning and LLMs, and why cognitive AI is the necessary path towards achieving AGI.Human Interaction and Intelligence: The importance of real-time learning, metacognition, and minimal sensory input in developing AGI.Ethics and Responsibility in AI: The philosophical and practical considerations of developing AGI, including the ethical implications and societal benefits.ResourceConnect with Peter AI fun fact articleAn episode you might like about the future of corporate VC

Dave is one of the original innovators in what is now known as 'dirty electricity' assessment and remediation.  We explore the origins of this space, effects on rats and people with specific information on most harmful frequencies, a little of what Dave learned from working with scientists in Russia, decreased use of asthma medicine and reduced insulin use, how to deploy in your own home, how to create your own whole-house DE filter, and my fantasy next gen DE filtration product.Support the Show.Support this podcast here: https://www.emfremedy.com/donate/Keith Cutter is President of EMF Remedy LLChttps://www.emfremedy.com/YouTube Channel: https://www.youtube.com/channel/UCp8jc5qb0kzFhMs4vtgmNlgKeith's SubstackThe EMF Remedy Podcast is a production of EMF Remedy LLCHelping you helping you reduce exposure to harmful man-made electromagnetic radiation in your home.

The Three Dimensions of Customer Value CreationRob Markey ought to know a thing or two about customer loyalty. Rob was a CX expert and thought leader at Bain long before he and his colleague Fred Reichheld introduced Net Promoter to the world. He is a leader in Bain's Customer Customer Strategy and Marketing practice and the co-author of The Ultimate Question 2.0 with Fred Reichheld.This episode was originally intended as a deep dive on customer loyalty through the customer lifecycle for my Michigan State University Master's students but it was just too good to not share in an episode.  As usual, Rob brings insights and wisdom to empower anyone interested in creating value for their customers starting with the three dimensions of value according Bain uses in their approach with clients. Also included in this episode:

Fresh from his exciting win of the Lasker Award - often dubbed the American Nobel Prize - Professor David Huang (USA) - the inventor of optical coherence tomography (OCT) - joins Prof Pearse Keane (UK) and Tunde Peto (Hungary/UK) to talk about how he and colleagues developed the technology and about the impact it has had on retinal medicine

Brian speaks with a team from NervGen Pharma. It is a Canadian start up trying to solve spinal cord injury. He is joined by:Dr. Harold Punnett, Co-FounderMike Kelly, President & CEO,Dr Jerry Silver, Co-Inventor & Scientific Advisor. NervGen Pharma's highly anticipated Phase II study of the potentially breakthrough drug NVG-291 in individuals with Spinal Cord Injury (SCI) isn't just “another clinical trial.” This drug has the potential to be transformational to the over 300,000 individuals who suddenly and without preparation or warning, suffered a life-altering traumatic injury resulting in either a significant disability or paralysis that has become “permanent” and with little to no hope for recovery or improvement.

Get ready to be inspired by our next guest, Alia Rahman, a true powerhouse in the BioTech industry! With a remarkable ability to multitask, Alia effortlessly juggles multiple roles, establishing herself as a force to be reckoned with. As the Co-founder & CEO of Amplexd Therapeutics and the Co-Inventor of Two Non-Invasive Cervical Dysplasia Treatments, Alia is on a mission to revolutionize women's health globally.Driven by her personal journey with dysplasia, Alia embodies the spirit of a patient-scientist, advocate, and innovator. Her relentless pursuit of developing non-invasive dysplasia treatments underscores her commitment to enhancing patient experiences, ensuring accessibility, and maximizing effectiveness. Alia's impressive background as an engineer, award-winning entrepreneur, keynote speaker, product developer, and executive leadership coach speaks volumes about her expertise and dedication. Her passion for advancing the BioTech and Cancer care space is truly inspiring, and her impact is bound to be far-reaching.Join us on this engaging podcast episode as Alia shares her invaluable insights into the BioTech industry. Discover her personal aspirations, delve into the groundbreaking work at Amplexd Therapeutics, and get a glimpse into her day-to-day life. Don't miss the opportunity to hear her perspectives on women's health, innovation, and the future of BioTech.And for a touch of fun, Alia will also take on our FemTech Five rapid-fire game, giving us a peek into her lighter side! Tune in and be inspired by Alia Rahman's remarkable journey and vision for a healthier future! DISCLAIMER: The content in the podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your doctor or qualified healthcare provider. Connect with FemTech India Website: https://www.femtechindia.com/Linkedin: https://www.linkedin.com/company/femtechindiaorg/Twitter : https://twitter.com/Femtech_india?t=HIyteldoOxSIAXwsEXYv4w&s=09Instagram: https://www.instagram.com/femtechindia_podcast?igsh=bzd4a2ZheXc0cm1sYoutube : https://www.youtube.com/@TheFemTechIndiaPodcast Connect with Navneet Linkedin : https://www.linkedin.com/in/navneet-kaur-80109b227/Twitter : https://twitter.com/Navneet_Kaurrrr

#035 Let's discuss the advantages of UPN and how it can support the human-centric BPM approach.In this episode, I'm talking to Walter Bril about the main aspects of Universal Process Notation (UPN) and how it supports the human-centric BPM approach. We discuss the five questions that need to be answered and compare it to other notations such as BPMN 2.0. What is the advantage of UPN? Do you really not need swim lanes to model processes in a lean way? Let's find out..Today's Guest:Walter BrilWalter is the co-inventor of UPN. He developed UPN in the early 2000s alongside several colleagues at Nimbus, a company later acquired by TIBCO.Before joining Nimbus, Walter worked as a Process Consultant for various companies in the Netherlands. Today, he holds the position of Customer Success Manager at Elements.cloud, a platform that can also be utilized for mapping processes in UPN.Walter lives in Nuth, located in the southern Netherlands, close to the German border and not far from Aachen.You'll learn:What the core principles behind the lean and clear approach of UPN areWhat UPN looks likeWhat the five essential questions of UPN areHow to adopt UPN's human-centric approach as an alternative to traditional BPMN 2.0 methodsHow to start using UPNI hope, you enjoy this episode of the New Process Podcast and are curious to learn more in the next episode. Hit subscribe to not miss it!If you'd like to get the links and show notes for this episode, head to:https://www.NewProcessLab.com/episode35---Follow me on LinkedIn:https://www.linkedin.com/in/mirkokloppenburg/Want to know how to start rethinking processes? Get my free checklist here: http://www.NewProcessLab.com/checklist

Drs. Vamsi Velcheti, Taofeek Owonikoko, and Janakiraman Subramanian discuss their experiences navigating the cancer drug shortage in the United States, the impact on patients and clinical trial enrollment, lessons learned, and proactive strategies to mitigate future crises. TRANSCRIPT  Dr. Vamsi Velcheti: Hello, I'm Dr. Vamsi Velcheti, your guest host for the ASCO Daily News Podcast today. I'm a professor of medicine and director of thoracic oncology at the Perlmutter Cancer Center at NYU Langone. On today's episode, we'll be discussing the impact of the shortage of cancer chemotherapy drugs across the United States. This has been affecting several thousands of patients with adult and pediatric cancers and hampering enrollment in clinical trials. Among the shortages are very commonly used drugs like cisplatin, carboplatin, methotrexate, and fludarabine. Some of these shortages have persisted since the time of the pandemic in 2020.   So today, to discuss this really troubling scenario, I have two outstanding colleagues, Dr. Janakiraman Subramanian, the director of thoracic oncology at Inova Schar Cancer Institute in Virginia, and Dr. Taofeek Owonikoko, a professor of medicine and the chief of the Division of Hematology and Oncology at the University of Pittsburgh Hillman Cancer Center in Pittsburgh.   Our full disclosures are available in the transcript of this episode, and disclosures relating to all episodes of the podcast are available at asco.org/DNpod.  So, a recent survey by the NCCN found that 90% of the nation's largest cancer centers have experienced a shortage in carboplatin, and 70% of the centers have reported a shortage in cisplatin. These are platinum-based chemotherapies we use frequently in patients with cancer, and these are often curative intent treatments for several cancers, and these are used in several tumor types, both solid tumors and hematologic malignancies. So, the scale of the problem is immense.   Dr. Owonikoko, I'd like to hear your take on this situation and how are you dealing with this at the UPMC Cancer Center.  Dr. Taofeek Owonikoko: Yeah, thank you, Dr. Velcheti, and happy to be part of this panel. As you rightly surmised, the chemotherapy drug shortage is what we've all experienced across the length and breadth of the United States. Our cancer center here in Pittsburgh is not an exception. We've had to be proactive as well as think outside the box to be able to manage the challenge. Just like every other cancer center across the country, maybe to varying degrees, we've had to look at patients in need of chemotherapy with these standard-of-care agents such as cisplatin or carboplatin, and to some degree docetaxel, during this past episode of drug shortage that we all went through. And while we did not have to, fortunately, cancel any patient treatment, we all went through it with bated breath; not sure of where the next batch of chemotherapy drugs will come through, but I would say in the past couple of weeks, we've actually seen some improvement in drug availability.   But before then, we've had to have contingency plans where, on a weekly basis, we review our patient list and the drug regimens that they're going to need, and must make sure that we have enough drug on hand for those patients. And in situations where we thought we might not have enough drug; we also had a plan to use alternative regimens. We were proactive in having guiding principles that are consistent with ASCO's recommendations in terms of quality care delivery for cancer patients. So, I'm sure that this is more or less the same approach adopted by other leading cancer centers across the country.   Dr. Vamsi Velcheti: Thank you, Dr. Owonikoko. And Dr. Subramanian, you're in a community setting, a large cancer center that serves a lot of patients in the state of Virginia. So, what is the scale of the problem at your institution and how are you handling it?   Dr. Janakiraman Subramanian: First of all, Dr. Velcheti, thanks for having me here on this panel. And as you rightly said, this is a significant problem, and it is across the country like Dr. Owonikoko said. And as medical oncologists, we are not always thinking of drug shortages. Our focus is on taking care of our patients. So, this is one more issue that we need to keep in mind now as we manage our patients with cancer. When this shortage started, the biggest problem, as you know, was when we became aware of this was primarily in cisplatin and we had some of our patients who were getting curative treatment and we had to make a decision - can they get cisplatin or can they get carboplatin. And one of the things we did was to have an ethics committee that will review each patient that is being planned to receive cisplatin-based chemotherapy and come to a decision on how best we can support them.   The template for some of this was based upon some of the triage mechanisms we used during COVID, as well as the ASCO guideline document for managing this chemotherapy shortage, which was one of the blueprints we used. And they have reviewed all cases, all patients that are being planned for cisplatin or carboplatin for that matter, and we come to a decision based on that. And we also have another committee that constantly monitors drug availability on a weekly basis and tries to forecast where the next problem would be as we take care of our patients.   And particularly as a lung cancer doctor, we've had situations where we had to use carboplatin instead of cisplatin and even we also have carboplatin shortage. And so, the committee usually approves two cycles at a time, but thankfully so far we have not had a situation where we could not offer our patients the chemotherapy treatment. But we are very carefully monitoring the situation, hoping that this will improve.   The other aspect of the shortage has been in 5FU. A lot of our GI colleagues; I treat esophageal cancer patients as well, where we've had to forego the bolus 5FU and have a 10% reduction on all 5FU infusions. And we've been using some of that dose reduction to ensure that we can have 5FU available for all our patients. And that's how we've been trying to manage this shortage situation here at Inova Schar.   Dr. Vamsi Velcheti: Dr. Subramanian and Dr. Owonikoko, we are oncologists, we are treating patients, and the toughest part really is telling a patient that we don't have access to certain drugs and we have to switch treatments to perhaps another treatment regimen that may be suboptimal. And it's always a very anxiety-provoking discussion, and especially for patients with metastatic cancer, they're already under a lot of stress and it's a really difficult conversation. How do you handle that, Dr. Owonikoko?  Dr. Taofeek Owonikoko: That's a conversation we all hope we don't have to have. And fortunately, with this current crisis, I've actually not had such misfortune of having to inform a patient that we don't have drugs to treat them or that we have to switch to something inferior. But conceptually, it's possible that could have happened and that would have been very difficult. But the one thing that we did, though, as part of our mitigation strategy was actually to inform the patient ahead of time because the way we handled this was to look at our inventory on a week-by-week basis. And if there are patients where we felt maybe they will be coming in towards the end of the week and we may not have enough drugs for them, to let them know the possibility exists that we might have to switch them to something different. While we did not have to do that for any patient, yes, there are patients that we had to give that heads up to, to say, “We're having this shortage. We're doing everything we can to make sure it's available. But just in case it's not available…” I think what is most important for most patients is to be aware of that decision ahead of time, to be able to process it, and to be transparent.   The other challenge that we face was, if you have to choose between patients, what should be your guiding principles as to who gets the drug and who doesn't get it? I think it's very easy for all of us to say, “Oh, if it's curative intent, we do it. If it's not curative intent, we don't do it.” It's a little more complicated than that because if we put the equity hat on, curative intent doesn't actually mean that that life is more valuable than somebody who cannot be cured. And this is where really, I think having people with expertise in ethics of care delivery and disaster management will be very important for us to proactively anticipate that, should this become a recurrent problem in the future that we actually have a well-vetted approach, just like we did during COVID where you have to ration resources that we have those people with expertise to help us as oncologists because not all of us, at least personally I can speak for myself, that is not my area of expertise and comfort.  Dr. Vamsi Velcheti: Excellent points. Dr. Subramanian, anything to add?  Dr. Janakiraman Subramanian: Oh, absolutely. I echo what Dr. Owonikoko said. These are conversations that we would like to hopefully never have with our patients. But this is a crisis that we are facing now. And personally, I can tell you two situations where we ran into this problem. But overall, though, we never had to stop a treatment or cancel a treatment for our patient. In the first situation, we had a young man with a rare germ cell tumor in the hospital for whom cisplatin was key. He was already in the ICU and sometimes the treatment start dates are not perfect, unlike what we do in the outpatient setting, depending on how well he's doing or the treatment start dates might move by a day or so. So we basically had to hold a certain dose of cisplatin for him.   This brings the next question, which is how do we decide who gets cisplatin versus who can go for an alternative option? And I think Dr. Owonikoko made a great point where, just because it is a curative disease does not mean their life is more valuable. This is where I think trying to make that decision at an individual level, as an individual treating physician can be extremely hard. And that's why at our institution we have this ethics committee where we have oncologists, pharmacists, and ethicists that review these chemotherapy orders, particularly for cisplatin, and try to use some guiding principles that we learned from COVID as well as ASCO's guidance to decide how we assign our resources. That's one option, one way we have done it.    And then in another situation that was faced by one of my GI oncology colleagues was a patient that was originally planned to go on a clinical trial where the chemotherapy backbone was FOLFOX and because we had the 5FU shortage, we could not offer that patient clinical trial enrollment. And that was a tough conversation where they had to tell them that they could not go on a clinical trial that they were looking forward to. And this then brings the next question, which is by foregoing the bolus 5FU and by the 10% reduction in the infusional 5FU, are we providing them inferior treatment? And it's a conversation that's had at a very individual level. I don't envy my colleague who had to have that conversation. It's a challenge and we try to do our best to communicate to our patients that we are trying to provide care without trying to compromise the effectiveness of treatment for them.  Dr. Vamsi Velcheti: Thank you so much both of you. And we had the same issues here at NYU in New York City as well. It appears, you know, the degree of shortage and the drugs that are in shortage has been somewhat different at different locations across the United States. But the theme has been that we are having to ration treatments for our patients. And of course, there are some tumor types where there's really no adequate substitution, for example, GU cancers. I mean, you can't really not give them cisplatin. A lot of these are situations which have curative intent and young patients. So, it's really troubling.   And I think one of the things that really came out of this is there's been a lot of push from professional societies that actually ASCO has been spearheading and some intense discussions with CMS and legislators to kind of provide more long-term fix for these things. And I think all of us have to be more engaged in those discussions with our professional societies like ASCO to kind of help promote awareness. So if you kind of think about it, these drugs are not that expensive. These are generic drugs that we've all been using for such a long time. And the fact that we can't provide these drugs for various reasons is kind of really concerning. We spend so much money on research and more expensive drugs and not being able to manufacture these drugs within the country and kind of having to rely on complex supply chains is troubling, and I hope the situation improves very soon.    So, I know both of you are at large cancer centers that enroll patients on clinical trials. Of course, these drugs, especially carboplatin, for lung cancer, especially, are like core treatments that are used in managing cancer patients with lung cancer. So how is this affecting your clinical trial accrual? Are you prioritizing patients on clinical trials for these drugs? Have you had to make any decisions to hold clinical trial accrual for certain trials? Kind of curious to hear.  Dr. Taofeek Owonikoko: Yeah, so I can maybe weigh in a little bit on that in terms of what we've had to do for patients receiving treatment as standard of care versus those going on clinical trials. As we all recognize that when a patient goes on a clinical trial, even if they are going to receive a standard-of-care regimen as part of that trial, it still has to be administered in line with the protocol. So, during the extreme period of shortage anxiety, we actually had consideration for perhaps not putting patients on trial if we're not sure that they will be able to continue to receive the protocol-mandated treatment, whether it's a control intervention or the experimental intervention.   The good thing to come out of this is at least here at UPMC, we actually did not have any instance where we had to deny a patient clinical trial participation. But there were anxious periods when we already had patients enrolled and they were scheduled to receive a platinum-containing regimen and we were not sure whether or not we were going to have adequate supply of the drug for them while on trial. I think this really raises an important consideration going forward as we come out of this current shortage. I don't by any stretch of the imagination assume that this is going to be the last one we experience, but I think the lessons learned here, we have to also carry that forward both in the design of the trial as well as in the regulatory environment surrounding clinical trial conduct, to say, should another incidence of drug shortage are to happen, how do we actually operationalize that with respect to patients on trial, whether starting or already on trial?   I think it's much more challenging when the patient is already on the trial, they've already started. It's less challenging if you just have to make a decision about somebody starting newly on the trial. But equally important is that by not allowing new patients to go on trial is denying something that potentially could be of benefit to them, albeit it is still a trial, it's not an established treatment option yet.  Dr. Janakiraman Subramanian : I completely agree with Dr. Owonikoko. Those were very key points and issues that we face as well. In terms of my patients with lung cancer, we haven't had a problem in getting them on clinical trials. Even though we have had carboplatin shortage patients who are already on treatment, they were able to get the carboplatin. For new patients, we were still able to provide them carboplatin as well. The biggest problem for clinical trials has been primarily with my GI colleagues who have to use 5FU. And there, as I said before, we are unable to give bolus 5FU and there is a 10% reduction of the infusional 5FU. So, we can't have any of these patients go on clinical trials.    And as a result, anything that has to do with 5FU has come to a screeching halt in terms of clinical trials for our patients. And I think I echo the point of Dr. Owonikoko that by no means this is the last drug shortage we're going to be dealing with and we are here today discussing this, also because this shortage has not ended. It's been ongoing. It's one of the longest drug shortages in my memory as a medical oncologist, and that's concerning. We still see that there is some improvement, but we haven't gotten past it yet.     And therefore, as we develop clinical trials and we need to have methods to address drug shortages and how we manage patient enrollment as well as how do we manage existing patients who are already on a clinical trial and, if possible, what might be their options in that situation. We may not have all the answers, but it is definitely an issue that we need to think about in the future as we develop and implement newer clinical trials for our patients.  Dr. Vamsi Velcheti: I completely agree and great points, both of you. And we've had the same issues with clinical trials at NYU Langone as well due to the shortage. It's been a challenge, and I think this is a problem that's so complex because of supply chain issues and the way the drugs are priced and incentives for manufacturing these drugs in the United States are not lucrative enough to actually onshore a lot of the production of these drugs.   I think at the end of the day, I think we have to come up with some creative, innovative, reimbursement structures for these generic chemotherapy drugs. I think this would require a very complex economic solution that perhaps ASCO and other organizations should kind of really foster an environment of innovation to kind of help facilitate onshoring some of the manufacturing of these key drugs within the United States. I think ASCO is already trying to do that, trying to collaborate with all the stakeholders to kind of address this problem is very critical, and I think all of us have to be engaged in some of the advocacy efforts that are ongoing to kind of address these drug shortages. And this is not a short-term problem.  So, Dr. Owonikoko and Dr. Subramanian, any final thoughts before we wrap up the podcast today?  Dr. Janakiraman Subramanian: So, Vamsi, you mentioned the whole complex supply chain and the fact that we rely primarily on overseas manufacturers to get these drugs that are off-patent but still a key backbone of our cancer treatment. I think those are all key issues that policymakers and leaders in the field have to keep in mind. As an institution at Inova, one of the key mechanisms that have helped us to sort of stay ahead of the shortage was to have this inventory management team that monitors the inventory out there. And in fact, the inventory management team does have access to what the inventory is in some of their main suppliers in terms of the drugs. And they also have an idea of how many patients are going through treatment, what is the weekly usage of a specific drug like carboplatin. And they try to forecast what is coming down the road and try to prepare for it.   And as we try to look for solutions, maybe a forecasting mechanism in a larger scale like either spearheaded by ASCO or by policymakers level that can, for the overall country, try to see where some of the inventory is for some of these critical drugs and try to prepare for it ahead of time, rather than wait till we hit the shortage and then try to find alternative suppliers to get the drug, which obviously doesn't happen quick enough. It takes months or even longer to catch up and get the inventory back to the level where we can comfortably take care of our patients.  I think that is something we should be advocating for that as well as the professional societies should take a handle on that and see if they can support something like that as well as letting the institutions know ahead of time what's coming might be very helpful.  Dr. Vamsi Velcheti: Yeah, very good point, Janakiraman, and I think that's a key takeaway here. I think we have to learn from other industries and try to– I mean this is not unique to healthcare by any means. I mean these chronic shortages due to supply chain issues, inventory management, there might be some learnings from other industries here that we probably should also focus on inventory management and improve supply chain logistics.   Dr. Owonikoko, any closing thoughts?   Dr. Taofeek Owonikoko: Yeah, I agree as well with all the points made by Dr. Subramanian and yourself. This is a chronic problem that requires a long-term strategy. I think it's both an economic problem as well as a regulatory problem. As we all know, part of the reason why we went through this current crisis is the regulatory decision by the FDA regarding safety of one of the manufacturers. So being proactive in terms of how these audits are conducted and giving people lead time I think will help avoid similar situations in the future.    It's an economic problem. There's a reason why a lot of the big pharma companies are not producing these drugs. And if the cost of production is such that the amount of money you get paid is enough to cover your price, I think there is an economic issue there to be addressed. That is unfortunately not within the scope of what any one of us can do individually, but as advocates in terms of the structure of incentivizing new drug versus old drug, some of these newer drugs are quite expensive, but oftentimes they are used along with standard drugs that are not as expensive. So, where do we strike that balance where we do not stifle innovation but at the same time, we don't create a perverse incentive system where everybody just wants to come up with the newest, most expensive drug and nobody is interested in really producing the backbone chemotherapy and other agents that will make those new drugs work well.   So, I think we have to pay attention. We have to advocate for our patients through our different institutions and organizations, and I hope that society as a whole that we've learned a lot of lessons from this crisis and that will help us craft some long-term strategies.   Dr. Vamsi Velcheti: Thank you both Dr. Owonikoko and Dr. Subramanian for your time today to speak with me and our listeners and for sharing your insights with us on the ASCO Daily News podcast.   Dr. Taofeek Owonikoko: Thank you.   Dr. Janakiraman Subramanian: Thank you.  Dr. Vamsi Velcheti: And thank you to our listeners for your time today. If you value the insights that you hear on ASCO Daily News Podcast, please take a moment to rate, review and subscribe wherever you get your podcast. Thank you so much.  Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  ASCO Resources Related to Drug Shortages are available here.     Follow today's speakers:    Dr. Vamsidhar Velcheti    @VamsiVelcheti    Dr. Janakiraman Subramanian  @RamSubraMD  Dr. Taofeek Owonikoko  @teekayowo    Follow ASCO on social media:     @ASCO on X (formerly Twitter)    ASCO on Facebook    ASCO on LinkedIn      Disclosures:     Dr. Vamsidhar Velcheti:     Honoraria: ITeos Therapeutics    Consulting or Advisory Role: Bristol-Myers Squibb, Merck, Foundation Medicine, AstraZeneca/MedImmune, Novartis, Lilly, EMD Serono, GSK, Amgen, Elevation Oncology, Taiho Oncology, Merus    Research Funding (Inst.): Genentech, Trovagene, Eisai, OncoPlex Diagnostics, Alkermes, NantOmics, Genoptix, Altor BioScience, Merck, Bristol-Myers Squibb, Atreca, Heat Biologics, Leap Therapeutics, RSIP Vision, GlaxoSmithKline      Dr. Janakiraman Subramanian:  Consulting or Advisory Role: AstraZeneca, Boehringer Ingelheim, Pfizer, Novartis, Daichi, G1 Therapeutics, Jazz Pharmaceuticals, Janssen Oncology, Lilly, Blueprint Medicines, Axcess, BeiGene, Cardinal Health, Takeda, OncoCyte  Speakers' Bureau: AstraZeneca, Boehringer Ingelheim, G1 Therapeutics, Jazz Pharmaceuticals, Janssen Oncology  Research Funding (Inst.): G1 Therapeutics, Tesaro/GSK, Novartis, Genentech, Novocure, Merck   Dr. Taofeek Owonikoko:  Stocks and Other Ownership Interests: Cambium Oncology, GenCart, Coherus Biosciences  Consulting or Advisory Role: Novartis, Celgene, Abbvie, Eisai, GI Therapeutics, Takeda, Bristol-Myers Squibb, MedImmune, BerGenBio, Lilly, Amgen, AstraZeneca, PharmaMar, Boehringer Ingelheim, EMD Serono, Xcovery, Bayer, Merck, Jazz Pharmaceuticals, Zentalis, Wells Fargo, Ipsen, Roche/Genentech, Janssen, Exelixis, BeiGene, Triptych Health Partners, Daichi, Coherus Biosciences  Speakers Bureau: Abbvie  Research Funding (Inst.): Novartis, Astellas Pharma, Bayer, Regeneron, AstraZenece/MedImmune, Abbvie, G1Therapeutics, Bristol-Myers Squibb, United Therapeutics, Amgen, Loxo/Lilly, Fujifilm, Pfizer, Aeglea Biotherapeutics, Incyte, Merck, Oncorus, Ispen, GlaxoSmithKline, Calithera Biosciences, Eisai, WindMIL, Turning Point Therapeutics, Roche/Genentech, Mersana, Meryx, Boehringer Ingelheim  Patents, Royalties, Other Intellectual Property (Inst.):   Overcoming Acquired Resistance to Chemotherapy Treatments Through Suppression of STAT3  Selective Chemotherapy Treatments and Diagnostic Methods Related Thereto  DR4 Modulation and Its Implications in EGFR-Target Cancer Therapy Ref: 18089 PROV (CSP) United States Patent Application No. 62/670,210 June 26, 2018 (Co-Inventor)  Soluble FAS ligand as a biomarker of recurrence in thyroid cancer; provisional patent 61/727,519 (Inventor)  Other Relationship: Roche/Genentech, EMD Serono, Novartis  Uncompensated Relationships: Reflexion Medical           

Successful Collaborators with Paul McEnroe, co-inventor of the Bar Code.Become a supporter of this podcast: https://www.spreaker.com/podcast/success-made-to-last-legends--4302039/support.

Inventor of Telegraph and Co-Inventor of Morse Code --- Send in a voice message: https://podcasters.spotify.com/pod/show/rocky-seale7/message

The Personal Computer Show Wednesday March 29th 2023 PRN.live Streaming on the Internet 6:00 PM Eastern Time IN THE NEWS  Gordon Moore, Intel Co-Founder Passed Away at Age 94  Turing Award Won by Bob Metcalf, Co-Inventor of Ethernet Technology  Non Disparagement Clauses Disallowed In Severance Agreements  FTC Ban Non Compete Clauses  Cable and Satellite Providers Required to Display True Price of Service  Pinduoduo with Hundreds of Million Users Accused of Distributing Malware  Work from Home Employees Fallen to 16.4% in 2022 ITPro Series with Benjamin Rockwell  2 Factor Authentication in Our Lives From the Tech Corner  Listening to Over 30,000 Radio Stations Around the World  World Backup Day – March 31, 2023  Judge Ruled Group of Book Publishers Over Internet Archive's Online Library  Artificial Intelligence vs Ancient Sport of GO Technology Chatter with Benjamin Rockwell and Marty Winston  Electric Vehicle Insights.

OVERVIEW: "Fortune favors the bold." – Latin Proverb Jason A. Duprat, Entrepreneur, Healthcare Practitioner, and Host of the Healthcare Entrepreneur Academy podcast, sits down with Joey Ferry, Nurse Entrepreneur, Co-Founder of Frontier Innovations Inc., and Co-Inventor of the Award-Winning SafeSeizure Pad. In this episode, we hear the story of how two innovative minds came together to revolutionize Healthcare through their Entrepreneurial vision. From the challenges they've overcome to the solutions they create, Joey's innovation paved the path toward their "good fortune."   3 KEY POINTS: You'll get to where you need to be, but take it one step at a time. To start a business, know what you're good at and talk to people about that. Sales expertise boils down to repetition.   EPISODE HIGHLIGHTS: Joey has a strong passion for entrepreneurship, even as a child. He once veered away from his Entrepreneurial passion and pursued Nursing for its financial security. Later, upon meeting his now business partner, Taofiki, he realized he could pursue both Entrepreneurship and Healthcare without sacrificing either. They discovered they had the same entrepreneurial passion and decided to work together towards a common goal. Joey creates products for ether two reasons: Solving a problem and providing convenience, even without much financial gain Creating a viable and potential business opportunity When creating prototypes, it doesn't have to be the final product. You simply want to test, feel, and play with it. Be okay with accepting the solution that might look different than when you first started. Joey and Taofiki are registered nurses who invented a new way to pad bed rails for patients on seizure precautions in the hospital setting. They source their materials from Alibaba from a manufacturer who can make the products in their desired dimensions. Once their business got off the ground, the product's revenue fueled itself. They once had struggles with their inventory. Fortunately, they won the 2020 Innovation Award and received $50,000, wherein half was directly invested in solving their inventory concerns. Joey recommends Wave Apps, a free software for new businesses for handling invoices, adding various products, adding customers, etc. Joey recommends upgrading to a paid tool when your business begins to scale. Sales expertise boils down to repetition. If you're not too experienced in sales yet, you might feel as if you're "bothering" people. Joey and Taofiki maintain a solid personal connection with their customers by signing emails with their names and including their contact numbers. To know more about SafeSeizure, visit their website at https://www.safeseizure.com/ Feel free to connect with Joey Ferry and LinkedIn.   TWEETABLE QUOTES: "You'll get there, but a lot of folks will give up early because they're looking at Z rather than looking at A, B, and C. Focus on the next couple of steps and don't worry about X, Y, and Z yet." – Joey Ferry "For anybody looking to start a business, know what you know, know where you shine, what you're good at, and where you thrive, and talk to people that want that." – Joey Ferry   CONNECT WITH JASON DUPRAT LinkedIn | Facebook | Instagram | Youtube Email: support@jasonduprat.com Join our Facebook group: https://jasonduprat.com/group    RESOURCES: Want to become a Ketamine Therapy provider? Enroll NOW in The Ketamine Academy course: https://ketamineacademy.com/presentation Sign up for one of our free business start-up Masterclasses by heading over to https://jasonduprat.com/freemasterclass  Have a healthcare business question? Want to request a podcast topic? Text me at 407-972-0084 and I'll add you to my contacts. Occasionally, I'll share important announcements and answer your questions as well. I'm excited to connect with you! Do you enjoy our podcast? Leave a rating and review: https://lovethepodcast.com/hea  Don't want to miss an episode? Subscribe and follow: https://followthepodcast.com/hea   RELATED EPISODES: #284: BE OBSESSED OR BE AVERAGE: AN INNOVATOR'S GUIDE TO BUILDING A VIRTUAL CARE COMPANY WITH GUY FRIEDMAN #219: TRAVIS HORNSBY: TRUST IN YOUR BIGGEST INVESTMENT – YOURSELF #279: WHY IS IT SO IMPORTANT TO INVEST IN YOURSELF NOW MORE THAN EVER? #HealthcareEntrepreneurAcademy #healthcare #HealthcareBoss #entrepreneur #entrepreneurship #podcast #businessgrowth #teamgrowth #digitalbusiness

Walking the aisles of the Fancy Food Show in Las Vegas earlier this year, a gentleman stuck a sparkling wine glass in my face and said “Do you like wine?” I responded, “Is this a joke?” He went on to tell me that this was an Italian non-alcoholic sparkling wine that he and his wife had created. I have tasted many non-alcoholic wines and they all suck. With trepidation, I tasted it. This was a decent wine. I was shocked and impressed. Come on my show I said…turns out he is in So Cal and I met Marco Marano. 

Jeff Kutas is an innovator at heart.  Co-Inventor & Founder of MB Sentinel™ Enterprises the maker of top quality Mailbox & Box Sentinel Parcel Safes, 2021 Best Product Texas   2022 Texas ⭐️ Award Finalist 2022 Architecture Masterprize WinnerJeff saw an opportunity to make life easier for consumers + leaned into his knowledge expertise + friendships to bring it fruition.  MB Sentinel is a magical product that safeguards our door-to-door deliveries, from climate, package pirates + other challenges.  This conversation is wonderful. Jeff speaks about how after decades in the retail space, he decided to pivot (when many others could have stuck it out) to the next path of his business life- knowing that not making a decision is still a decision + how that enabled him + continues to be a pillar in his life.Jeff vividly talks about how he actually cares for the people in his world, reminds us that we can't do it alone + we get emotional about what it really means to give back + acknowledge the things that are bigger than you + I.Click on link about MB Sentinel or Box GobblerJeff Kutas can be reached directly hereOrder your MB Sentinel hereConnect with JonathanKeynote speaker, Consultant, Trainer + Performance Coach: www.jonathancinelli.comAuthor:  Kick Your Ego aside and Put People FirstEducation: ProjectBitesIG@jonathanacinellifacebook.com/jonathancinellipmSupport the showAppreciate the content we provide?Buy a coffee as a way of supporting the production of the showhttps://www.buymeacoffee.com/jcinelli

Part 2 of 2Predictive NPS - How Loyalty Measurement is Changing with Rob MarkeyA powerful, insightful, revealing interview so packed with gems that I had to break it into two parts!Rob Markey is the Co-Inventor of the Net Promoter System and the Co-Author of The Ultimate Question 2.0.In Part 2 (this episode):We discuss:Rob's definition of customer experienceThe impact of digital transformation on CXWhy and how NPS will still play a role despite the emergence of technologyThe evolution of NPS in a digital worldIs it moral and ethical to treat every customer the same? (hint - his answer may surprise you!)Rob Markey BioHas led dozens of successful customer-centric transformations at large, global companies​Creator of Bain's approach to customer-centricity​ Introduced Earned Growth through Customer Value Management in “Are You Undervaluing Your Customers,” Harvard Business Review, Jan-Feb 2020​ Co-inventor of the Net Promoter System; co-author The Ultimate Question 2.0; Leader of Bain's NPS Loyalty Forum​Founder of Bain's Customer Strategy and Marketing practice​30+ years at Bain​MBA, Harvard; BA, Brown​ Ran 7 marathons and aspires to complete all the world majors by 2024And by the way, happens to host his own podcast, The Net Promoter System PodcastSubscribe to The Delighted Customer Podcast so you don't miss an episode: https://www.empoweredcx.com/podcast Subscribe to The Delighted Customer Newsletter for practical tips and insights: https://www.empoweredcx.com/delightedcustomersnewsletter

Rob Markey on the Delighted Customers Podcast Part 1 of 2What would you expect from one of the top CX thought leaders in the world?A powerful, insightful, revealing interview so packed with gems that I had to break it into two parts!Rob Markey is the Co-Inventor of the Net Promoter System and the Co-Author of The Ultimate Question 2.0.In Part 1 (this episode):We discuss:Loyalty levers to pull in a down economyHow loyalty leaders can excel in a recessionWhy Rob initially rejected a single question to measure customer loyalty?This misinterpretation of Net Promoter ScoreWhy that one question was selected as the right question to measure customer loyaltyRob Markey BioHas led dozens of successful customer-centric transformations at large, global companies​Creator of Bain's approach to customer-centricity​ Introduced Earned Growth through Customer Value Management in “Are You Undervaluing Your Customers,” Harvard Business Review, Jan-Feb 2020​ Co-inventor of the Net Promoter System; co-author The Ultimate Question 2.0; Leader of Bain's NPS Loyalty Forum​Founder of Bain's Customer Strategy and Marketing practice​30+ years at Bain​MBA, Harvard; BA, Brown​ Ran 7 marathons and aspires to complete all the world majors by 2024And by the way, happens to host his own podcast, The Net Promoter System Podcast

Scott Stornetta is a Grandfather, Teacher, Investor and scientific researcher – and an invention he did 30 years ago totally revolutionizes the world of tech today. In 1991, he and Stuart Haber, published the whitepaper "How to Time-Stamp a Digital Document”. This paper, in fact, could be described as the invention of blockchain. In 1992 this paper won the Discover Award for Computer Software; it's considered to be one of the most important papers in the development of cryptocurrencies as we know it today.Tune into this fascinating conversation as we explore inventing blockchain by proving its impossibility, the current state of trust and blockchain's role in fixing it, stakeholders in mass adoption of timestamps and Web3 – and Self-Sovereign Identity (SSI) and how to get there.For full show notes visit https://thetrustedweb.org/podcast/.

This podcast was recorded in early November, on the sidelines of the Singapore Fintech Festival 2022. It was fitting in the spirit of the event to have Stuart Haber join Kopi Time. Dr Haber, along with Scott Stornetta, co-invented the blockchain technique in 1990, which was later adopted by Satoshi Nakamoto as the basic mechanism for data integrity in Bitcoin. We begin the conversation travelling back over three decades, to understand the problem and motivation that drove Haber and Stornetta toward the blockchain. It is clear even as young coders and crypographers, their ambition was high and their goal was to have transformative and lasting impact on the way civilisation's records are stored. We then talk about the seminal moment in 2008, when the Satoshi white paper came out, and Dr Haber's take on it then (and now). We tackle the questions of a crypto bubble, Bitcoin's adverse environmental impact (and possible solutions around it), proliferation of tech solutions looking for a problem, and the applications that appeal to him. Dr. Haber talks about his current research, and takes on my question on the potential impact of quantum computing on cryptograhy-based record authentication. A brilliant mind with outstanding insights.See omnystudio.com/listener for privacy information.

It's time once again for for us to kick back with our sketchbooks and coffee cups, as we Interview Jeff Kutas, Co-Inventor and Founder of MB Sentinel Enterprises, Entrepreneur, and Published Author. On this episode, we talk about his company - which focuses on designing parcel safes and mailboxes. Additionally, he gives advice as a CEO, and tips and tricks for young designers, and those interested in potentially kicking off their own businesses. The blog is located at architecturecoffeeandink.com which also has the complete link of all my sources, previous episodes, and old blog posts posted a few hours after each episode comes out. You can email me at architecturecoffeeandink@gmail.com, or head over to the Insta, @architecturecoffeeandink,as well as the TikTok, @architecturecoffeeandink. MB Sentinel Enterprises can be found at https://mbsentinel.com/.

Know Stroke Podcast -S4E3-Henry Hoffman On this episode we were joined by Henry Hoffman,MS,OTR/L co-inventor and co-founder of Saebo, Inc. We were introduced to Henry through Dr. Carolyn Brown, a previous guest of the podcast in season one. Saebo, Inc. is a medical device company primarily engaged in the discovery, development and commercialization of affordable and novel clinical solutions designed to improve mobility and function in individuals suffering from neurological and orthopedic conditions. With a vast network of Saebo-trained clinicians spanning six continents, Saebo has helped over 100,000 clients around the globe achieve a new level of independence. About our Guest: Henry graduated from D'Youville College in Buffalo, NY in 1997 with a Masters degree in occupational therapy. Since graduation, he has worked in a variety of settings including home health, acute, sub-acute, and outpatient rehab. Prior to leaving Burke Rehabilitation Hospital in New York, he worked as a clinical specialist in orthopedic medicine and manual therapy of the upper quadrant. Henry left Burke in the fall of 2002 to co-launch Saebo. This was a great discussion and as co-hosts we share a common mission with Henry to continue to dispel the believe that stroke recovery has an end when a “plateau” is reached. Listen in to learn how Henry and his team are on a mission to offer new affordable treatment options that deliver tangible results, and offer hope and support for continued recovery and improved function. Learn more about Saebo's mission and connect with Henry here. In the News mentions:  Neurology Live Show Credits: Music Credit and Podcast Production by Jake Dansereau, connect at JAKEEZo on Soundcloud @user-257386777 Be sure to give the show a like and share, +follow and connect with us on social or contact us to be a guest on the  Know Stroke Podcast

Guest BioArlen is the co-Inventor of MQTT – The leading protocol for IoT( Internet of Things), specializing in Industrial Internet of Things (IIoT) and SCADA software solutions. With over 40 years of experience in the SCADA & IIoT industry, Arlen has broad experience covering the design and manufacture of embedded computer systems to complete SCADA system infrastructure implementations for many companies. A leading expert on MQTT involved in many activities including published articles and speaking engagements on educating the use of publish/subscribe methodologies for operational technologies and digital transformation. Main Discussion Points How and why MQTT was invented The adoption of MQTT as a lightweight and modern protocol How IIoT has forced us to rethink many of the legacy ways we've been working on automation and manufacturing. Theme: IIoTManufacturing Hub Episode 67.Big thank you to Phoenix Contact for sponsoring this theme and for your continued support of the community.Recommended Materials- The C Programming LanguageConnect with Us Arlen Nipper Vlad Romanov Dave Griffith Manufacturing Hub Let Us Know What You ThinkIf you enjoyed the show, it would mean the world to us if you could leave us a review: https://podcasts.apple.com/us/podcast/manufacturing-hub/id1546805573#automation #manufacturing #IIoT #MQTT

In today's episode, John speaks with Dag Kittlaus, Co-Inventor of Siri and current Co-Founder/CEO at Riva Health.  They Discuss What Did Steve Jobs Originally Want to Call Siri? What is the Biggest Healthcare issue in the world? How many people that are prescribed blood pressure meds don't fill their prescription? How did Siri help catch a Killer? Enjoy! To make sure you never miss an episode of The High EQ Market podcast, subscribe on Apple Podcasts, Spotify, and the website. Listening on a desktop & can't see the links? Just search for The High EQ Marketer in your favorite podcast player.

Cedar Anderson the Co-Inventor, CEO & Co-Founder of Flow Hive and the Flow Hive technology that has been hailed as the biggest innovation in beekeeping since 1852 joins Enterprise Radio. The post Flow Hive, the biggest innovation in beekeeping since 1852 appeared first on Enterprise Podcast Network - EPN.

Yahoo Finance Tech Editor Dan Howley speaks with iPhone & iPod co-inventor Tony Fadell about his new book 'Build' as well as the future of technology. See acast.com/privacy for privacy and opt-out information.

Caroline's Cart and transportation for special needs individuals while shopping in store Drew Ann Long, Co-Founder of Caroline's Cause and Co-Inventor of Caroline's Cart with Hannah Burt Wilson _ Alabama Care is partially supported by http://www.ACDD.org The views expressed are not necessarily the views of these organizations.

The Personal Computer Show Wednesday March 2, 2022 PRN.live Streaming on the Internet 6:00 PM Eastern Time IN THE NEWS o David Boggs, Co-Inventor of Ethernet o Restrictions on High Tech Exports to Russia o Russian Invasion Fallout and the International Space Station o Ukraine's Supply Chain Role in Global Semiconductor Production o Computer Chip Industry Begins Halting Deliveries to Russia o ARM China Seizes IP, Relaunch as Independent Company IT Pro Series with Benjamin Rockwell o What is Software Volume Licensing From The Tech Corner o 3 Months and 700 Steps to Produce a Computer Chip o Intel High Performance Computer - 1 exaFLOPS Ponte Vecchio Technology Chatter with Benjamin Rockwell and Marty Winston o Subaru Accident Leads to New Car Technology

THANKS TO AN INVENTION IN THE 70S.. PEOPLE CAN SEND AN EMAIL OVER AN OFFICE NETWORK… OR VISIT A WEBSITE THROUGH A COFFEE-SHOP HOTSPOT.. WITH BOB'S WORLD.. I'M BOB WELCH THE CO-INVENTER OF ETHERNET.. DAVID BOGGS HAS DIED… MORE IN A MINUTE --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app --- Send in a voice message: https://anchor.fm/bobwelch/message

Dr. Mehdi Peikar is the Chief Medical Officer, Chief Technology Officer, Co-Inventor and Co-Founder of BRIUS Technologies. A practicing orthodontist, Dr. Mehdi has a passion for using technological advances to give patients a great experience with their orthodontia. Tune in to this episode of People & Practice as Amy and Dr. Leon chat with Dr. Mehdi and his take on the role of advancing technology and orthodontics. We cover important topics like: [02:00] Dr. Mehdi introduces himself and explains his background and work with BRIUS [07:19] How Dr. Mehdi came up with BRIUS Technologies using his education in physics and biomechanics [10:44] Design and production of BRIUS as an independent mover for patients [15:00] The efficiency of independent movers vs. traditional wires and brackets [23:16] Dr. Mehdi answers a question from a fellow orthodontist and listener about what to look forward to as technology advances   Key Takeaways: Keeping up with technology and trends will help keep orthodontic practices relevant and work more efficiently. Office visits can get to be inconvenient and consumers want less visits and quicker results- using advanced technology can help practices do this for it's clients About Dr. Mehdi Peikar: Dr. Mehdi Peikar is the Chief Medical Officer, Chief Technology Officer, Co-Inventor and Co-Founder of BRIUS Technologies. Dr. Peikar is a practicing orthodontist who graduated from the UCLA School of Dentistry. He also holds a Master's degree in Quantum Mechanics and Condensed Matter from the University of Illinois and a Ph.D in Biomechanics from Johns Hopkins University. Dr. Peikar's unique background in academia, and passion for revolutionizing the orthodontic experience continues to drive product development and success in achieving superior biomechanical results. https://pplpractice.com/

In this episode of Beltway Broadcast, your Metro DC Chapter of ATD hosts Brian Washburn. Brian is the Co-Inventor of Soap Box and Co-Founder and CEO of Endurance Learning. He is an instructional designer, podcaster, speaker, and the author of What's Your Formula? Combine Learning Elements For Impactful Training and multiple articles for TD Magazine. In this episode, Brian describes the Presenter Quadrant, discusses presenting styles, and shares how presenters can focus on the necessary strategies to enhance their practice.     If you'd like to learn more about Brian, checkout his LinkedIn profile or visit his company's website.   For more info about the Metro DC Chapter of ATD, visit DCATD.org.  Episode Credits: Series Announcer: Julie Waters Hosts: Christina Eanes, Stephanie Hubka, Laëtitia Gnago, and Halyna Hodges

Dr. Madhavi Gavini is the Co-Founder, Co-Inventor, and CEO of Droplette, a technology company revolutionizing skincare with a breakthrough device of the same name. Regarded as the latest revolutionary skincare gadget, Droplette is a transdermal delivery tool that delivers active ingredients under the skin. Madhavi is also the President and Co-Founder of Novopyxis, an award-winning biotechnology company dedicated to developing therapeutics and medical devices. Dr. Madhavi Gavini joins me today to discuss revolutionizing and democratizing skincare and beauty. She explains how Droplette solves the inefficiencies of topical drug application and describes how it avoids the side effects of common skin treatments such as peels. She shares what inspired the creation of Droplette and her advice for women seeking other women co-founders. She also highlights the foundations young people should build if they are to embark on entrepreneurship and science and describes how trailblazing women continue to impact women in STEM today. “The skin is the largest organ in your body and tends to be the last one to receive nutrients and support. It's not just about beauty; it's about the health and wellness of your skin.” - Madhavi Gavini This week on Girls in Tech: The genesis of Droplette and how Madhavi met her co-founder Droplette's medical, skincare, and cosmetic applications What Epidermolysis Bullosa (BD) is and how it inspired Madhavi and her co-founder to create a transdermal device How Droplette shifted from initially treating EB to skincare Democratizing beauty and skincare and how Droplette adapted its marketing amid COVID-19 Why Droplette is an effective solution for drug delivery Other dermatological issues Madhavi is invested in Madhavi's advice on finding a woman co-founder The impact of trailblazer women in STEM Research and Development: other tech Madhavi and Droplette are interested in working with What it feels like to invent a novel technology that improves peoples' lives Connect with Madhavi Gavini: Droplette Droplette on LinkedIn Droplette on Instagram Droplette on Facebook Droplette on Twitter Madhavi Gavini on LinkedIn Inspiring Girls in Tech...One Conversation at a Time Thanks for tuning into this week's episode of Girls in Tech. If you enjoyed this episode, please subscribe and leave a review wherever you get your podcasts. Apple Podcasts | TuneIn | GooglePlay | Stitcher | Spotify | iHeartRadio Be sure to share your favorite episodes on social media to help us reach more listeners, like you. Join us on Facebook, Twitter, Instagram, and LinkedIn. For more exclusive content and information, visit our website.

This week on The Encrypted Economy, we are joined again by Dan Bogdanov, Director of the Information Security Institute at Cybernetica and the Co-Inventor of Sharemind. With a Ph.D. in Informatics and a master's degree in Computer Science, Dan shares his expertise on digitization initiatives and privacy preservation. Be sure to subscribe to The Encrypted Economy for more perspective on countries leading in the adoption of privacy-enhancing tools and other innovative technologies. Topics Covered:· Introduction· How Do Privacy Enhancing Technologies Enable Outsourcing Functions?· Discussing Functional Encryption · What Differentiates Sharemind?· Using MPC with Federated Learning Frameworks· Sharemind's Vision for the Future· Addressing Privacy Washing· The Digital Identity EvolutionResource List:· Dan's LinkedIn· Dan Bogdanov Twitter · Cybernetica· Sharemind· Homomorphic Encryption· Multi-Party Computation· Zero-Knowledge Proofs· Federated Learning· IOS 15 ID StorageFollow The Encrypted Economy on your favorite platforms! Twitter LinkedIn Instagram Facebook      

Dr. Paul A. Offit, MD, (https://www.paul-offit.com/) is an internationally recognized expert in the fields of virology and immunology, Co-Inventor of a landmark vaccine for the prevention of Rotavirus gastroenteritis, and holds multiple titles including - Director of the Vaccine Education Center at Children's Hospital Of Philadelphia (CHOP), Maurice R. Hilleman Chair of Vaccinology and Professor of Pediatrics, Perelmann School of Medicine, University of Pennsylvania, and Adjunct Associate Professor, The Wistar Institute of Anatomy and Biology. Dr. Offit was a member of the Advisory Committee on Immunization Practices to the Centers for Disease Control and Prevention, a founding advisory board member of the Autism Science Foundation and the Foundation for Vaccine Research, a member of the Institute of Medicine, and co-editor of the foremost vaccine text, Vaccines. Dr. Offit is a recipient of many awards including the J. Edmund Bradley Prize for Excellence in Pediatrics from the University of Maryland Medical School, the Young Investigator Award in Vaccine Development from the Infectious Disease Society of America, a Research Career Development Award from the National Institutes of Health, and the Sabin Vaccine Institute Gold Medal. Dr. Offit has published more than 150 papers in medical and scientific journals in the areas of rotavirus-specific immune responses and vaccine safety. He is also the co-inventor of a landmark rotavirus vaccine recommended for universal use in infants by the CDC. For this achievement, Dr. Offit received the Luigi Mastroianni and William Osler Awards from the University of Pennsylvania School of Medicine, the Charles Mérieux Award from the National Foundation for Infectious Diseases, and was honored by Bill and Melinda Gates during the launch of their Foundation's Living Proof Project for global health. In addition, he has received numerous other awards and honors for his groundbreaking work. Dr. Offit is also an author of many books including, but not limited to: Vaccinated: One Man's Quest to Defeat the World's Deadliest Diseases, Overkill: When Modern Medicine Goes Too Far, The Cutter Incident: How America's First Polio Vaccine Led to the Growing Vaccine Crisis, Breaking the Antibiotic Habit, Do You Believe in Magic, and his most recent, You Bet Your Life: From Blood Transfusions to Mass Vaccination, the Long and Risky History of Medical Innovation.

MEET DELIC is almost upon us! For our appreciation of listening to this podcast, use code RADIONAUT for 20% off General Admission. Head over to www.meetdelic.com to get your tickets! This episode dives into the science of pain relief through ketamine treatments, anesthetics, nerve blocks, and other techniques with regenerative medicine specialist Dr. Matt Cook, and we get real and personal with Dr. David Rabin MD, PhD,  a board-certified psychiatrist and Co-Founder, and Co-Inventor at Apollo Neuroscience about the power of touch for stress relief.  We discuss:  - Ketamine - Dosage Safety Windows - The dangers of fentanyl - Endometriosis - Regenerative medicine - Human touch for stress relief in times of crisis - Much more

This week on The Encrypted Economy, my guest is Dan Bogdanov, Director of the Information Security Institute at Cybernetica and the Co-Inventor of Sharemind. With a Ph.D. in Informatics and a master's degree in Computer Science, Dan shares his expertise on digitization initiatives and privacy preservation. Be sure to subscribe to The Encrypted Economy for more perspective on countries leading in the adoption of e-governance tools and other innovative technologies. Topics Covered:·       Introduction·       Dan's Background·       Why Does Estonia Take the Lead in Digitalization?·       E-Residency and E-Voting in Estonia·       Forming a Company in Estonia with E-Governance·       Privacy-Enhancing Technologies in E-Voting Systems·       Discussing the Partnership Between Cybernetica and Estonia·       Is Homomorphic Encryption a Solution for Privacy Preservation·       Estonia's Digital Currency Initiatives·       OutroResource List:·       Dan's LinkedIn·       Dan Bogdanov Twitter ·       Cybernetica·       Sharemind·       Tom Attema Episode·       Estonia's E-Governance  ·       Estonia Digital Currency R&D·       Cybernetica partners with PwC Middle East ·       Cybernetica Smartphone-Based ID authentication ·       University of Tartu and Cybernetica Cooperate to Study Quantum-Safe Cryptography ·       Panel Discussion: Lessons on How to Make Data Run, Not People  Follow The Encrypted Economy on your favorite platforms! Twitter LinkedIn Instagram Facebook      

FuelPositive Corporation (TSX.V: NHHH) (OTCQB: NHHHF) (“FuelPositive” or the “Company”) has hired engineer Dr. Ghassan Chehade, one of the co-inventors named on the provisional patent of the Company's technology that will produce carbon-free ammonia (“NH3”). Dr. Chehade worked with Dr. Ibrahim Dincer on the original development of the Company's core NH3 technology. He has joined the Company as Lead Project Engineer. To view the full press release, visit https://nnw.fm/PSd7q

FuelPositive Corporation (TSX.V: NHHH) (OTCQB: NHHHF) (“FuelPositive” or the “Company”) has hired engineer Dr. Ghassan Chehade, one of the co-inventors named on the provisional patent of the Company's technology that will produce carbon-free ammonia (“NH3”). Dr. Chehade worked with Dr. Ibrahim Dincer on the original development of the Company's core NH3 technology. He has joined the Company as Lead Project Engineer. To view the full press release, visit https://nnw.fm/PSd7q

Dr. Madhavi Gavini is the Co-Founder, Co-Inventor, and CEO of Droplette, a technology company revolutionizing skincare with a breakthrough device of the same name. Regarded as the latest revolutionary skincare gadget, Droplette is a transdermal delivery tool that delivers active ingredients under the skin. Madhavi is also the President and Co-Founder of Novopyxis, an award-winning biotechnology company dedicated to developing therapeutics and medical devices. Madhavi joins me today to discuss revolutionizing and democratizing skincare and beauty. She explains how Droplette solves the inefficiencies of topical drug application and describes how it avoids the side effects of common skin treatments such as peels. She shares what inspired the creation of Droplette and her advice for women seeking other women co-founders. She also highlights the foundations young people should build if they are to embark on entrepreneurship and science and describes how trailblazing women continue to impact women in STEM today. “The skin is the largest organ in your body and tends to be the last one to receive nutrients and support. It's not just about beauty; it's about the health and wellness of your skin.” - Madhavi Gavini This week on Girls in Tech: The genesis of Droplette and how Madhavi met her co-founder Droplette's medical, skincare, and cosmetic applications What Epidermolysis Bullosa (BD) is and how it inspired Madhavi and her co-founder to create a transdermal device How Droplette shifted from initially treating EB to skincare Democratizing beauty and skincare and how Droplette adapted its marketing amid COVID-19 Why Droplette is an effective solution for drug delivery Other dermatological issues Madhavi is invested in Madhavi's advice on finding a woman co-founder The impact of trailblazer women in STEM Research and Development: other tech Madhavi and Droplette are interested in working with What it feels like to invent a novel technology that improves peoples' lives Connect with Madhavi Gavini: Droplette Droplette on LinkedIn Droplette on Instagram Droplette on Facebook Droplette on Twitter Madhavi Gavini on LinkedIn Inspiring Girls in Tech...One Conversation at a Time Thanks for tuning into this week's episode of Girls in Tech. If you enjoyed this episode, please subscribe and leave a review wherever you get your podcasts. Apple Podcasts | TuneIn | GooglePlay | Stitcher | Spotify | iHeartRadio Be sure to share your favorite episodes on social media to help us reach more listeners, like you. Join us on Facebook, Twitter, Instagram, and LinkedIn. For more exclusive content and information, visit our website.

NasalGuard ® Airborne Particle Blocker ® is a drug-free electrostatic topical nasal gel that prevents airborne particles from entering the nose. The product is drug-free and safe for children, the elderly, pregnant or nursing women, and those concerned about potential drug interactions with other medications. Kanika Wahi is Co-Founder and Co-Inventor of newly patented enhanced formulation of NasalGuard technology a division of Trutek. Trutek is a privately held company which has developed innovative airborne contamination prevention medical devices, nasal particle blockers and skincare products. NasalGuard ® Airborne Particle Blocker wants everyone to Breathe Easier this year. It is Allergy Season and people are getting vaccines for COVID-19, for travel or to protect from other airborne allergens and pollutants, this ‘invisible mask' worn under your mask will make life safer for you and your loved ones. --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app

Dr. Richard Schatz is research director of cardiovascular interventions at the Scripps Heart, Lung, and Vascular Center and director of gene and stem cell therapy. His work in coronary stents launched a revolution in the treatment of coronary artery disease; over 2 million stents are placed each year. His work has had an immeasurable impact on prolonging life and reducing healthcare costs.This episode covers a cardiologist's perspective on the carnivore and low-carb diets, how the role of randomized controlled trials has changed over time, what to do to stay heart healthy.We also discuss advice for being an inventor. This includes the importance of being first to file, building a daily inventing habit, and knowing the basics of patent law. Finally, we discuss the emotional impact of having influenced 100+ million people, why his design worked, and what it was like to engage with world leaders like Lee Kuan Yew and Mother Theresa. Help The Louis and Kyle Show:If you enjoyed this episode, please share it with a friend!If you want to reach out to us, please do so on Twitter: https://twitter.com/LouisKyleShowEmail us: LouisandKyleShow@gmail.com

In this episode, Dr. Taofeek Owonikoko, lung cancer specialist at the Winship Cancer Institute at Emory University and chair of the 2021 ASCO Annual Meeting Education Program, discusses the diverse ways that cancer care equity will be featured during #ASCO21.   Transcript ASCO Daily News: Welcome to the ASCO Daily News podcast. I'm Geraldine Carroll, a reporter for the ASCO Daily News. My guest today is Dr. Taofeek Owonikoko, a lung cancer specialist at the Winship Cancer Institute at Emory University. Dr. Owonikoko serves as the chair of the education program of the 2021 ASCO Annual Meeting. And he's here to tell us about the diverse sessions that will be featured this year. Dr. Owonikoko reports no conflicts of interest relating to our discussion today. His full disclosures and those relating to old episodes of the podcast are available at asco.org/podcast. Dr. Owonikoko, it's great to have you on the podcast today. Dr. Taofeek Owonikoko: Thank you. Glad to be here. ASCO Daily News: Health equity is the major theme of this year's Annual Meeting. And as you know, ASCO's President, Dr. Lori Pierce, has been focusing on patient care equity during her term. Can you tell us about how the concept of cancer care equity has been incorporated into the education program this year? Dr. Taofeek Owonikoko: Thank you very much. I actually want to use this opportunity for us to thank all the ASCO volunteers, who spent countless hours putting together a very educational program for the Annual Meeting. It's very difficult for me to come out and say [that] this is the best session to go to. I think all of the sessions are very important and educational. The challenges that we've faced with COVID-19 that is making this a virtual meeting, actually, I think is an opportunity for people to be able to participate in all these sessions. Having said that, there are some sessions that we intentionally placed within the Education Program based on how important we felt these topics were to our patients, to their caregivers, family members, and also to ASCO members. We want sessions that focus on various aspects of health equity from individual patient interaction with their providers, to patient experience within the larger context of how health care systems are built, and how we deliver care. Some of the sessions that I really encourage members to listen to and participate in will be--there is a session that is going to bring diverse viewpoints from across the world, not just in the U.S. We want to see how oncologists practice in a limited resource setting, how they go about taking care of patients, and how they are able to use the challenges that they face as a stepping stone to bring the best care forward for that patient. So we have this session where we're going to have a speaker from Uganda in Africa. We have another speaker from Pakistan representing the Asian viewpoint. We are going to have a speaker who will speak to delivering care to the inner city population here in the U.S. And that session will also have a speaker that will discuss how we take care of our patients within the Native American community here in the U.S. So you're going to see these diverse viewpoints that we feel will shed light on the important point that Dr. Pierce has been trying to make with the presidential theme, that we need to focus on every patient, everywhere in terms of equitable care delivery. ASCO Daily News: Intersectionality in cancer care is a topic that has been getting more attention over the past year. How will this issue be addressed during the Education Program? Dr. Taofeek Owonikoko: We've talked about determinants of health outcomes for patients. How we look at all of these issues in isolation, whether it's gender, sexual orientation, race or ethnic background, rural versus urban, big city versus small towns, and different regions of the world. There's actually now this emerging consensus that a lot of these factors actually do not stand alone. There is an intersection of where someone lives and what type of access they have to health care--where someone lives and what type of care providers, someone's gender, and their socioeconomic status influencing the outcomes of care that they get. So this session on intersectionality, I think will really bring this to the forefront of our discussion about how to address health inequities--that we don't want to focus on one issue at a time. All these issues are important and they are interrelated. I think this type of session will help all of us to understand that there's a lot going on that determines the outcome for patients, especially for patients with cancer. One additional session I want to highlight, which is also very important to the presidential theme is the session on viruses and cancer. While there is this pandemic with the COVID-19 virus that we are very aware of, what we also did not want to lose sight of is the fact that viruses are etiology for cancer. This has been a topic that we've been struggling with for decades. And now that everyone is paying attention to the COVID-19 virus and development of a vaccine to prevent the infection or make the severity less for those who eventually get infected, I think we also need to bring that focus back to what viruses have done as etiology for different types of cancer--from either neck cancer to cervical cancer to liver cancer. And bringing this session together which speaks to how viral infection could be a key driver of the geographical differences in incidence of cancer around the world, I think will be very important for ASCO members and the general audience attending the meeting. ASCO Daily News: Absolutely, well you spoke about the pandemic and of course today health care inequality is more relevant than ever. As you say, the pandemic has disproportionately affected people of color, so clearly changes must occur if the oncology field if it is to make strides in improving outcomes for patients of color, increasing representation in clinical trials, for example, improving access to precision medicine and more. So what do you hope that people will take away from this meeting, that will stay with them in the months and years ahead? Dr. Taofeek Owonikoko: Yeah, I'm very hopeful that at the end of the Annual Meeting, with all the offerings we have in terms of educational sessions and topical issues that we want to address and some of them very provocative, we will learn that we have to be honest and open. Some of these issues are not easy to discuss, but we have to confront them if we are going to get past that, and not just brush them aside but actually have genuine discussion and be open about what the challenges are. I think that, when we look at the impact of cancer care delivery and the disparate outcomes that we see across different minority communities, including people of color, this doesn't just start from where you're delivering care, it also has to do with how we actually develop treatments that are given to patients. And nothing brings that to the surface [more] than what we've observed in terms of participation of people of color in cancer clinical trials. I know that this is a vaccine issue it's not something that I just started today, but we have to then become more systematic as to how we address it. If we are going to develop drugs that are going to be applicable to all populations, we have to be intentional in making sure that we have equitable and fair representation of all people, and that the treatment would be applicable too, so that we can start learning right from the beginning of the earliest stages of drug development. Whether there are unique differences in the way these drugs work, whether there are cultural influences that would determine whether or not the way we want to administer the drug is going to have any impact. And I want to use this to highlight one session that we have put together that's going to talk about minority patient enrollment in clinical trials. This session is not about the problem. We all recognize what the problem is. This is actually a session that is meant to show potential solutions, where we invited experienced investigators in this area to talk about gaps in how we conduct clinical trials, and what can be done to improve that process. They will talk about communications and blind-spots that we as oncologists and investigators may not even be aware of when we talk about clinical trials and we want someone to participate--what are the things that we can do to make sure that we convey the information about this study in a culturally appropriate manner, so that our own attitude of presenting the trial does not alienate and discourage participation from people of color and other minority groups? And then, there will be a talk about a real world experience of a large trial where key factors led to success in recruiting people of color on a large randomized phase III trial of prostate cancer that will be shown and shared with the audience. And people can take this back home to their individual practices and countries to see whether or not some of these strategies will also be applicable to them to help get around this problem of poor enrollment of minority patients in cancer clinical trials. ASCO Daily News: Thank you, Dr. Owonikoko, for highlighting some of these important issues on minority enrollment in cancer clinical trials, intersectionality, and cancer care, the management of DNA virus associated cancers, and the always popular ASCO voices session, which this year will use the power of the narrative to advocate for equity in cancer care. Dr. Owonikoko, thank you again for taking the time to speak with me today. Dr. Taofeek Owonikoko: Thank you. ASCO Daily News: And thank you to our listeners for joining us as well. If you're enjoying the content on the podcast, please take a moment to rate, and review us wherever you get your podcasts.   Disclosures: Dr. Taofeek Owonikoko Stock and Other Ownership Interests: Cambium Oncology Consulting or Advisory Role: Novartis, Celgene, Abbvie, Eisai, G1 Therapeutics, Takeda, Bristol-Myers Squibb, MedImmune, BerGenBio, Lilly, Amgen, AstraZeneca, PharmaMar, Boehringer Ingelheim, EMD Serono, Xcovery, Bayer, Merck, Jazz Pharmaceuticals, Zentalis, Wells Fargo, Ipsen, Eisai, Roche/Genentech, Janssen Speakers' Bureau: Abbvie Research Funding (Institution): Novartis, Astellas Pharma, Bayer, Regeneron, AstraZeneca/MedImmune, Abbvie, G1 Therapeutics, Bristol-Myers Squibb, Corvus Pharmaceuticals, United Therapeutics, Amgen, Loxo/Lilly, Fujifilm, Pfizer, Aeglea Biotherapeutics, Incyte, Merck, Oncorus, Ipsen, GlaxoSmithKline, Calithera Biosciences, Eisai, WindMIL, Turning Point Therapeutics, Roche/Genentech, Mersana, Meryx, Boehringer Ingelheim Patents, Royalties, Other Intellectual Property (Institution): OVERCOMING ACQUIRED RESISTANCE TO CHEMOTHERAPY TREATMENTS THROUGH SUPPRESSION OF STAT3, SELECTIVE CHEMOTHERAPY TREATMENTS AND DIAGNOSTIC METHODS RELATED THERETO, DR4 Modulation and its Implications in EGFR-Target Cancer Therapy Ref:18089 PROV (CSP) United States Patent Application No. 62/670,210 June 26, 2018 (Co-Inventor), Soluble FAS ligand as a biomarker of recurrence in thyroid cancer; provisional patent 61/727,519 (Inventor) Other Relationship: Roche/Genentech, EMD Serono Uncompensated Relationships: Reflexion Medical Disclaimer: The purpose of this podcast, is to educate and to inform. This is not a substitute for professional medical care, and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

A solid with a liquid microstructure that can be molded any way we want. Glass is a material we often take for granted, but it has been essential to the development of modern technology. From buildings to the screen of our phones and medicine vials, glass is all around us. Although it's been used for thousands of years, new glass compositions and manufacturing techniques are transforming the way we communicate, build, and interact with technology.     Today's guest is Dr. John Mauro, a Materials Science Professor at Penn State University. In this episode, Dr. Mauro guides us through the composition, manufacturing methods, applications, and interesting facts about Glass!   In this conversation, we discuss the following topics: What is glass? (0:59) Is glass actually ceramic? (3:25) Common applications of glass (6:50) Glass for safety in transportation and autonomous vehicles (10:03) Glass used for soft-tissue repair (12:26) Antimicrobial glasses (16:40) The science behind Gorilla glass (18:55) Fiber optics and communication (22:51) Glass in the biomedical field (28:29) Aesthetics and Architecture (33:13)   Reach out to Dr. Mauro:  https://www.linkedin.com/in/john-mauro-b6285b58 jcm426@psu.edu   Join our Discord community! You can meet other passionate materials scientists and engineers from around the world, discuss the latest breakthroughs in MSE, share materials-related memes, and get career advice from experts in the field.   For shorter segments, subscribe to our channel on YouTube. For bloopers, audiograms, and interesting materials science articles, follow us on Instagram, LinkedIn, and Twitter. Feel free to message us on our social media platforms if you have any feedback or recommendations for future episodes, or email us directly at itsamaterialworldpodcast@gmail.com. Finally, reach out to David Yeh and Punith Upadhya on LinkedIn if you'd like to chat about the latest breakthroughs in MSE!   Disclaimer: Any opinions expressed by either guests or hosts in this show are their own, and do not represent the opinions of the companies or organizations with which they are affiliated.  

Greg Hunt is Senior Research Chemist for Strategic Research at the Lubrizol Corporation. Greg has a PhD in Chemistry from England’s 3rd oldest University - Durham University. He has published 18 research papers and has a handful of patents on corrosion. Additionally, Greg is Co-Inventor of the wire corrosion test. This discussion is centered on the role of fluids for electric vehicle propulsion systems, with a focus on the risks, causes, and mitigation of wire corrosion. This topic is critical as we look to improve efficiency and lifetime for electric vehicles. To address this issue, Lubrizol and FEV have collaborated to provide the innovative Wire Corrosion Test for anyone working in this field. This test is the first of its kind and is optimized to provide quick, quantitative feedback to assist in the development and validation of corrosion-resist fluids. Contact either Greg or Brandon through LinkedIn to learn more. https://www.linkedin.com/in/gregory-hunt-6a84ab28/ https://www.linkedin.com/company/the-lubrizol-corporation/ https://www.lubrizol.com/ The Future of Mobility podcast is focused on the development and implementation of safe, sustainable, and equitable mobility solutions, with a focus on the people and technology advancing these fields. https://www.linkedin.com/in/brandonbartneck/ http://brandonbartneck.com/futureofmobility/ Music credit: Slow Burn Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 3.0 License

CRISPR, the gene editing technology, has caused a revolution in science. It’s also raised thorny ethical questions.  Learn more about your ad choices. Visit megaphone.fm/adchoices

PODCAST EPISODE 21: Cedar Anderson, Flow Hive co-inventor, Byron Bay, Australia While the recording of this episode might be a little crackly in parts, I feel it represents something of the character of my next guest. Inventor, entrepreneur, bee lover, family man, paraglider, Flow Hive co-creator – Cedar Anderson is a truly down-to-earth bloke with truly down-to-earth (yet highly ambitious) passions. The chat we had – recorded, on his end, from underneath his house – crackles in parts, like an earthy laugh, and seems indicative of Cedar's grass-roots approach. However, this analogy doesn't quite paint the picture of just how switched on and inspiring Cedar truly is. An ABC article by Vanessa Gorman perfectly summed up Cedar's evolution in its title: ‘From humble hippie to multi-millionaire businessman — the man who revolutionised the beehive'. Cedar and I first met when I went to visit him with Simon Mulvany (from Save the Bees) at his home in Broken Head, near Byron Bay, in the spectacular Northern Rivers area of New South Wales; however, I had heard of him long before that trip and was excited to meet him in person. What you take from meeting this lovely man is that he is dedicated to his family, he loves and appreciates nature, he is an inspiring businessperson, and that his connection to bees has allowed him to create a system for extracting honey that is both unique and effective. This third-generation beekeeper has been inspiring the beekeeping community in Australia and abroad with his new ideas and environmental ethos – check out his TEDxBrisbane Talk, ‘Why the World Needs Backyard Inventors' if you haven't already. So, what is this revolutionary invention Cedar co-invented, you might ask? The Flow Hive presents a new way of extracting honey from Langstroth-style European honeybee hives. While understanding that the most important aspect of any honey production process is respect for the animal and looking after a colony as best as humanly possible, a system like the Flow Hive changes the honey extraction process completely through “an artificial foundation made from BPA- and BPS-free food grade plastic, manufactured right here in Australia, on which the bees build their comb”. The bees fill the artificial cells with honey and cap them off. Then, a “Flow Key” is inserted to split the cells, and gravity helps the honey flow into the trough, through tubes and straight into your honey jars! With an incredible 48,000+ customers in over 139 countries, the Flow Hive is building even stronger connections between keepers and bees. Tune in to hear Cedar and I talk about the Flow Hive, inventing, family, eco-business and stumbling upon a 30-year-old bee box mid-podcast! https://www.honeyflow.com.au https://www.bensbees.com.au

Steve, Dan, and Holly introduce Scotty Bolleter, one of the co-inventors of the EZ-IO. Scotty details how he got started in EMS, and what led him to help create the EZ-IO. Scotty discusses his time as a flight paramedic, and how his time spent training in hospitals pushed him into EMS business ventures. Steve touches on his business ventures in EMS. Scotty walks the trio through his team’s process of modifying older devices to create their version of the EZ-IO. Scotty talks about his inter-disciplinary team of physicians, engineers, and others. The correct process of placing a humeral IO is discussed, from positioning the patient to proper placement for insertion. The process of IO flow is explained. Scotty discusses possible complications if an IO is placed wrong. Scotty discusses the use of the distal femur IO placement in cardiac arrest at his department. IO placement in the femur versus the humerus or the tibia is compared. Pediatric IO placement is reviewed. Scotty highlights the open IO, and when it is indicated. Correct IO placement is recapped, and Scotty touches on why EMS providers should not bury an IO needle into the bone. Steve reviews a call on a patient in status seizure where an IO is used for access.

Dr. David Rabin joins to show to talk about his revolutionary invention, Apollo, and how this device is being used to successfully address stress and psychological disorders in ways that conventional treatments can not. On today’s podcast, you will learn: Why Stress interferes in recovery outcomes. Why meditation and breath-work benefits are so short lived. How you can use wearable technology to remain in a relaxed state and beat stress before it beats you. How Dr. Rabin’s invention, the Apollo, is being used to address conditions resistant to conventional treatments like addiction, PTSD, depression, etc. Dr. David Rabin's Bio: Dr. David Rabin MD, PhD, a board-certified psychiatrist and translational neuroscientist, is the Chief Innovation Officer, Co-Founder, and Co-Inventor at Apollo Neuroscience; the first scientifically-validated wearable system to improve HRV, focus, sleep, and access to meditative states by delivering gentle layered vibrations to the skin. Dr. Rabin is helping to organize the world’s largest controlled study of psychedelic medicines in collaboration with colleagues at Yale, the University of Southern California, Mt. Sinai, and MAPS (Multidisciplinary Association of Psychedelic Studies) to determine the mechanisms of the dramatic therapeutic benefits observed following psychedelic-assisted psychotherapy in treatment-resistant mental illness. Learn more about Apollo and get a special 15% off! Go to Are toxic metals causing your fatigue and health issues? Find out by taking Wendy’s Heavy Metals Quiz at

Roham Gharegozlou, Co-Inventor of CryptoKitties and Founder of Dapper Labs talks about scaling NFTs to billions of users and how the Metaverse, as an emergent ecosystem, will not be designed: it will be open fluid and anchored on a blockchain.

Mary Lou Keller is co-inventor of the patented Pulmonica Pulmonary Harmonica and Vice President of Harmonica Techs. She has a master’s degree in microbiology and works with her husband’s healthcare consulting business. She has been an infection control trainer, a wedding DJ, and a romance novelist. She is here to teach us how to Breathe Better Now, with practical tips to improve our breathing. If you have a book, or a complimentary gift you would like to giveaway – please indicate The Pulmonica sells for $99.95 on Amazon. For listeners of this program, email Mary Lou and she will sell you a Pulmonica for $70.00 plus tax and shipping.

Mary Lou Keller is co-inventor of the patented Pulmonica Pulmonary Harmonica and Vice President of Harmonica Techs. She has a master’s degree in microbiology and works with her husband’s healthcare consulting business. She has been an infection control trainer, a wedding DJ, and a romance novelist. She is here to teach us how to Breathe Better Now, with practical tips to improve our breathing. If you have a book, or a complimentary gift you would like to giveaway – please indicateThe Pulmonica sells for $99.95 on Amazon. For listeners of this program, email Mary Lou and she will sell you a Pulmonica for $70.00 plus tax and shipping.

Join Nicole and Stu Anderson as they talk all about the Flow Hive, including some of the common complaints found online!WHAT YOU’LL LEARNWhat are the benefits of the flow hiveGet to know Stu’s beekeeping experienceWhy Stu and his son made the Flow HiveBeekeeping in Australia vs the USStu addresses common complaints about the Flow HiveOUR GUESTIn this episode, Nicole talks to Stu Anderson, co-inventor of the Flow Hive.A long-time tinkerer, Stu has built several houses over the years (including the one in which Cedar was raised, and where Stu still lives with his partner, Michele) and co-designed and built an off-grid solar and water-powered electricity supply to serve a dozen homes on the cooperative.He’s also a life-long beekeeper and before the Andersons’ incredible invention became all-consuming, was the manager of a not-for-profit community organisation based in Lismore, NSW. As well as having a hand in the daily decision-making at Flow, Stu is the man on the mic, talking Flow Hive at numerous business and beekeeping conferences and other events, in Australia and abroad.Stu is still an avid beekeeper with a passion for the natural world and a family man with four kids and nine grandchildren. Stu alos plays mandolin in a bush band.WHAT IS A FLOW HIVE?An invention that has revolutionized the beekeeping industry – the Flow Hive contains Flow Frames, a world-first technology which allows the beekeeper to harvest honey straight from the hive without disturbing the bees.Regarded as the most significant advancement in beekeeping since 1852, the Flow Hive has removed the need for expensive processing equipment making the fascinating world of beekeeping much more accessible.Beekeeping has been in the Anderson family for three generations. A love for the bees and the natural world has always been an important part of the lives of the father-son inventing team behind the idea, Stuart and Cedar Anderson. It all started because Cedar felt bad about bees being crushed during the honey harvest. He was sick of being stung and having to spend a whole week harvesting the honey from his small, semi-commercial apiary.RESOURCES & LINKS MENTIONEDFlow Hive WebsiteFlow Hive FacebookFlow Hive TwitterFlow Hive InstagramFlow Hive YouTubeEmail us! Ask@HeritageAcresMarket.comSign up and be the first to know about future episodes and updates!- http://bit.ly/2CMza8m SUPPORT THE SHOWYour support helps us continue to provide the best possible episodes!View Our Favorites on Amazon*Shop HeritageAcresMarket.comFollow us on Facebook and InstagramJoin our Hens & Hives Facebook GroupJoin our VIP Text ClubLeave a question or comment on our podcast message page!#backyardbountypodcast #heritageacresmarketSupport the show (http://paypal.me/heritageacresmarket)

What if you had the ability to build a test environment to help you identify where and how your business needs to change.Something which allowed you to model the business and identify:Who was doing whatWhich systems they were usingHow information impacted their output.And then provided the most important things for you to focus on? With a digital twin for your organisation, that's exactly what you can have. A digital twin provides a representative model of how your business operates which means you can interact with the model and guide better decision making.Because gut based decisions don't drive better outcomesIn today's episode, I talk with Neil Calvert about digital Twins.About my gust:Neil Calvert is the CEO and Co-Inventor of the LINQ platform at LINQ Ltd. LINQ is an infonomics enabled Digital Twin platform, helping business leaders and their advisors who are loosing sleep over the stress of authorising change they do not understand, to gain the knowledge needed to make evidence-based decisions faster than ever before and effectively communicate the impact on people, systems and finances to everyone in the business. With a background in spatial information, helping organisations create increased value utilising the information asset has seen Neil's career evolve from mapping the globe to mapping the organisation. Based in Wellington, New Zealand, Neil enables companies and partners around the world to accelerate their digital transformation using the Digital Twin of the Organisation. Outside of work, Neil is a keen cook and practises Shaolin Kempo and Tai Chi. 

Wendy Robbins, founder of Nowhere To Millionaire LLC, and the “1,000,000 fulfilled and financially free women making a difference. She has been on her own since she was 14. She has been homeless, lived in a car and at another time in her life went from $10,000 debt to make millions by co-inventing and marketing The Tingler head massager. She is a leading expert on mastering the millionaire mindset, and how to manufacture and market ideas to millions. She stars in the TV series with Kelly Ripa, showing women how to manufacture, distribute and pitch her invention to HSN. The show airs on TLC. Wendy's book, “Why Marry A Millionaire? Just Be One! (And While You're At It, Change The World!” is being distributed by Hay House world-wide. She also is in a movie based on the classic book, “Think and Grow Rich.” The film is called, “Awaken Your Riches!” It is similar to The Secret and distributed by the people who published, “The Secret.” (Still a best selling book.) She is also in “The Source,” a film about how to be happy. She hosted a weekly radio show, “As You Wish!” for almost 3 years reaching half a million+ people, interviewing millionaires and Spiritual leaders. She has been on Montel, CNN, QVC, hundreds of local news shows, thousands of radio shows.

Dr. Chris Cetta is a board-certified orthodontist practicing with Blue Wave Orthodontics in Florida. He received his undergraduate degree from Wake Forest University in North Carolina and graduated from Rutgers School of Dental Medicine in New Jersey. Prior to specializing in orthodontics at Jacksonville University in Florida, Dr. Cetta was a practicing general and cosmetic dentist for several years. Dr. Chris Cetta is the co-inventor of Precision Aligner Buttons™ by DynaFlex. He is also the host of the Illuminate Orthodontic podcast which focuses on innovators and inventors in the profession. He also plays bass guitar for two rock bands, including the all-orthodontist group Relapse. In this episode… One common mistake many inventors make when they have a great idea is that they start making a product prototype without thinking through its execution and without considering whether to patent it or not. See, having a great idea is not good enough because an idea is only as good as the force that propels it to become a fruitful and realized endeavor. After coming up with his idea for aligner buttons, Dr. Chris Cetta knew he had a lot more to do and he continued to work hard into perfecting his invention. He not only got a patent for his product, he also took it to market and he worked on helping other orthodontists and inventors who were bound to go through the same process. In this episode of In Your Face podcast, Craig Weiss and Blair Feldman talk to the inventor of the Precision Aligner Buttons, Dr. Chris Cetta, about how he created the product, the challenges he faced in the process, and why he decided to patent the product. He also talks about his podcast and the segment of orthodontist he wishes to represent and how the COVID-19 pandemic is likely to affect the orthodontic and dental industry. Stay tuned.

Bob Metcalfe has lived in the future since the late 1950s. And lucky for the rest of us, he has brought us along for the ride. In this interview, Mike Maples Jr of Floodgate talks to him about the origins of networked computing as well as the birth of "Metcalfe's Law."

Privately shared info about Chloroquine is being blocked by Google, Twitter, and medium? JADonnelly was mentioned on the No Agenda Show, by Co-Inventor of Podcasting Adam Curry. NoAgendaShow.com MadPod.com, JADonnelly

My friend, Dr. David Rabin MD, PhD,  is a board-certified psychiatrist and translational neuroscientist, is the Chief Innovation Officer, Co-Founder, and Co-Inventor at Apollo Neuroscience; the first scientifically-validated wearable system to improve HRV, focus, sleep, and access to meditative states by delivering gentle layered vibrations to the skin. Dr. Rabin has also organized the world’s largest controlled study of psychedelic medicines in collaboration with colleagues at Yale, the University of Southern California, Mt. Sinai, Modern Spirit, and MAPS (Multidisciplinary Association of Psychedelic Studies) to determine the mechanisms of the dramatic therapeutic benefits observed following psychedelic-assisted psychotherapy in treatment-resistant mental illness.   Dr. Dave will speak at MeetDelic.com  Learn more about him at apolloneuro.com  

In this episode of Access Granted, I welcome my guest Bryce Johnson. Bryce works as the Inclusive Lead at Microsoft. He is also the co-inventor of the Xbox Adaptive Controller and is an ambassador for Accessibility within Microsoft and Xbox. Today Bryce and I talk about how the Adaptive Controller came about, their Super Bowl ad in 2019 and what Bryce hopes the future brings for accessibility in gaming.IF YOU ARE LOOKING FOR A TRANSCRIPT OF THE SHOW CLICK HERE: https://accessgrantedpodcast.simplecast.com/episodes/bryce-johnson-co-inventor-of-the-xbox-adaptive-controller/transcriptFollow Bryce JohnsonTWITTER: http://twitter.com/brycejYou can also follow Steve SaylorTWITTER: http://twitter.com/stevesaylorYOUTUBE: http://youtube.com/snowballMIXER: http://mixer.com/blindgamersteve

Let's forget about sustainability and talk about Beauty, Quality and Innovation. Michael Baumgart really gave us a whole new perspective on climate change - even more, on the role of humanity. In this episode you will find out why we should rather consider to celebrate life and humanity than constantly think about decreasing our footprints. At the end Nicolaj also prepared a special invitation if you search for a way to become a change-maker yourself. Just shoot us a message on Instagram to learn more.

En este episodio en conversación con Emilio Torres hablamos sobre diferentes temas relacionados con la educación y la tecnología en un mundo que tiene alto número de componentes de herramientas digitales, hablamos de inteligencia artificial, procesos de educación y la visión de la educación en Américalatina y Europa en Colegios, universidades y el gobierno. Emilio Torres es Director Pedagógico de www.progrentis.com para América y Europa, Coach profesional educativo, miembro de la Asociación Española de Coaching ASESCO y licenciado en Economía por la Universidad de Laguna (España). Co-Inventor de 3 patentes registradas en USPTO de EEUU sobre habilidades del pensamiento y procesos de metacognición y Embajador Parlamentario en España para el Parlamento Mundial de Educación (PAME). Experto en dirección de centros escolares por la Universidad de La Rioja (España). Master del profesorado por la Universidad Complutense de Madrid (España) y auditor educativo en la norma ISO 9001/2015 Europea para la gestión de calidad en centros escolares. Master en Neuroeducación y Neuropsicología por la Universidad de Nebrija (España), Master en metodologías activas por la Universidad de Alcalá de Henares (España) y formador experto en metodologías activas y planes estratégicos, habiendo acompañado a un centenar de instituciones en sus planes de innovación y capacitaciones metodológicas. Director del Colegio Salesiano de La Orotava (España y profesor de Economía y Matemáticas desde el 2007 al 2017. Conferencista y escritor de diferentes artículos de opinión relacionados con la innovación educativa. Entre el 2015 y el 2019 ha impartido mas de 300 conferencias educativas entre España y Latinoamérica. Invitado: Emilio Torres (www.progrentis.com) Producido por: Alejandro Pelaez Rodriguez Web site: https://www.apelaez.com/podcasts/transformacion-digitalBlog: https://www.apelaez.com/blogemail: alejandropelaezr@gmail.com Redes SocialesInstagram: https://www.instagram.com/alejandropelaezrYouTube: https://www.youtube.com/user/alejandropelaezrTwitter: https://twitter.com/apelaezFacebook: https://www.facebook.com/alejandropelaezr CreditosMusic by: Fontanez / Doug Maxwell - Urban LullabyFotografia: Juan Jose Alvarez Calle https://www.kreafoto.com

En este episodio en conversación con Emilio Torres hablamos sobre diferentes temas relacionados con la educación y la tecnología en un mundo que tiene alto número de  componentes de herramientas digitales, hablamos de inteligencia artificial, procesos de educación y la visión de la educación en Américalatina y Europa en Colegios, universidades y el gobierno. Emilio Torres es Director Pedagógico de www.progrentis.com para América y Europa, Coach profesional educativo, miembro de la Asociación Española de Coaching ASESCO y licenciado en Economía por la Universidad de Laguna (España). Co-Inventor de 3 patentes registradas en USPTO de EEUU sobre habilidades del pensamiento y procesos de metacognición y Embajador Parlamentario en España para el Parlamento Mundial de Educación (PAME). Experto en dirección de centros escolares por la Universidad de La Rioja (España). Master del profesorado por la Universidad Complutense de Madrid (España) y auditor educativo en la norma ISO 9001/2015 Europea para la gestión de calidad en centros escolares. Master en Neuroeducación y Neuropsicología por la Universidad de Nebrija (España), Master en metodologías activas por la Universidad de Alcalá de Henares (España) y formador experto en metodologías activas y planes estratégicos, habiendo acompañado a un centenar de instituciones en sus planes de innovación y capacitaciones metodológicas. Director del Colegio Salesiano de La Orotava (España y profesor de Economía y Matemáticas desde el 2007 al 2017. Conferencista y escritor de diferentes artículos de opinión relacionados con la innovación educativa. Entre el 2015 y el 2019 ha impartido mas de 300 conferencias educativas entre España y Latinoamérica. Invitado: Emilio Torres (www.progrentis.com) Comparte este podcast, deja tus comentarios y escríbenos que temas quisieras escuchar. Music by: Fontanez / Doug Maxwell - Urban Lullaby Fotografía: https://www.juanjalvarez.com Producido por: Alejandro Peláez Rodríguez https://apelaez.podbean.com/ alejandropelaezr@gmail.com  

Recognized as one of FORBES’ "25 Professional Networking Experts to Watch in 2015”, Mike Muhney’s career is uniquely and intensely focused on relationships. He thrives on helping people manage their entire network and everyone in them. His values-based principles come from an early career with IBM. That world-class company training developed his ability to partner in co-inventing software that launched the global CRM industry.ACT! Is that company - a product that in 1987 fashioned the entire Relationship Management software category and global industry today known as CRM (Customer Relationship Management). ACT! has been used by over 40 million people in the world and is still growing its customer base.Tune in and learn how two men with entrepreneurial spirits made this happen.

Join the conversation by jumping into The Video Insiders LinkedIn Group. If you would like to be a guest on the show, send an email to thevideoinsiders@beamr.com For more podcast episodes, click here. Learn more about Beamr's technology. Today's guest: Tamar Shoham.

Let's talk about how companies can overcome analysis paralysis, and get people to think differently about connecting decoupled data and devices into infrastructure. We're discussing how business leaders expecting IIoT to disrupt operations can have a comprehensive strategy moving forward. Today's guest is Arlen Nipper, the Co-inventor of MQTT. Learn more at inductiveautomation.com 

Join us as we speak with Anna Stork, co-inventor of LuminAID, the world’s first solar-powered inflatable light developed to provide disaster relief aid after the Haiti earthquake in 2010. Hear how two college friends crowdfunded the development and manufacturing of the technology and had the opportunity to pitch their invention for funding on Shark Tank. Through all this, the LuminAID light has become the new favorite product of outdoor adventurists while also providing aid to disaster-stricken communities around the world. See acast.com/privacy for privacy and opt-out information.

We are discussing how MQTT got started and how it has evolved over the years. Hear about the big technological developments impacting the industrial sector and what it takes to accelerate the adoption of real IIoT solutions. We’re coming together to combat common problems and major changes within the industry. Today’s guest is Andy Stanford-Clark, the co-inventor of MQTT. Learn more at inductiveautomation.com

Our special guest this week on SPED Homeschoool Conversations was Lisa Burginger, Co-Inventor of QubitsToy and Co-Owner of the Qubits Toy Company. Lisa shared on "Hands-On STEM Learning" Other topics covered in this video are teaching analytical mathematics to help students better grasp the concepts of theoretical math, makers fairs and spaces, teaching biology and gardening using construction toys, hands-on pre-engineering skill building, how toys influence child's later career choices, and using construction toys to build interpersonal and team relationships.

Mr. Gerhard Reichert is an industry expert with over 30 years of experience at the highest levels of insulating glass technology and innovation. With over 80 insulating glass patents worldwide, Mr. Reichert is considered an unmatched authority on insulating glass systems, components, procedures, and performance. He is the inventor and co-inventor of many foam spacer […]

David Rabin MD, PhD, Chief Innovation Officer, Co-Inventor & Co-Founder of Apollo Neuroscience joins us for a fascinating interview. Dr. Rabin is a psychiatrist and translational neuroscientist. He is also a member of the Modern Spirit Research Advisory Board. This is our first episode of the Emotional Biology 101 miniseries, exploring the intersection between biology, emotion, and spirituality. Join us for an interesting discussion covering modern mental health, emotional healing, psychedelic and vibrational medicine and much more.

Soothe Your Brain With Apollo Neuroscience Co-Founder, Dr. Dave Rabin. In this episode of the Deep Change Podcast, we explore stress resilience, the problem of chronic stress and different "bottom-up" stress reduction tips and tools and can cut the problem off at the knees! Check out Apollo's amazing work here: https://apolloneuro.com/ -------------- Dave Rabin is an MD / PhD in Neuroscience and Psychiatry, and is the Chief Innovation Officer, Co- Inventor & Co-Founder of Apollo Neuroscience. As a psychiatrist and translational neuroscientist, Dr. Rabin specializes in developing novel, non-invasive therapies for treatment-resistant physical and mental illnesses. His research focuses on chronic stress from the cellular and molecular level to the body as a whole. Dr. Rabin works to identify new healthcare markets, to evaluate Apollo’s real- world efficacy through clinical trials, and to guide development of the Apollo technology.

Dr Scott Stornetta: Co-Inventor of Blockchain on Crypto ClotheslineSpeaking with the original co-inventor of Bitcoin was such a warm and friendly experience... Nothing like you would imagine Satoshi Nakamoto would sound - If you believed the rumors that Dr Scott Stornetta is in fact Satoshi. It is safe to say we absolutely do not believe these rumors however there is still space for us to be wrong. Blockchain was not born together with Satoshi’s Bitcoin white paper, it had been mooching around for almost 20 years before Satoshi started creating new layers on top of the original protocol, thereby creating Bitcoin…Scott went on to tell us that although their processes were on track, technology was just not there yet as the biggest storage drive was just 10mb compared to our terabyte hard drives we have now. Chris Dorian of BuildSort asked the inevitable question of whether Scott Stornetta was in fact, the Satoshi Nakamoto? The response was interesting “I'm a fan of what he's done, but I do want to say that when Stuart and I first talked about the Bitcoin paper, we felt like some of it was just a great idea, out-of-the-box thinking... And then other parts of it we looked at and said: Why did he make that mistake? Why did he do that?” But as our audience, have a listen and see what you think..... Is Dr Stornetta the real Satoshi?

Today we met with Deryck Graham of First Digital Capital, who’s sponsoring the live community event ‘Blockchain Economy’ happening next week in Perth, on Tues 21st August with a view to attracting crypto enthusiasts, blockchain professionals, investors and those simply wanting to learn more about all of the above. The main purpose of the event being education and networking. Guest speakers include a veritable New York line up starting with Dr Scott Stornetta, Co-Inventor of the Blockchain, Dr David Yermack, Professor of Finance at NYU Business School and currently working for a month with the University of Western Australia, and Justin Dombrowski, CEO of Soho who is presently collaborating with First Digital Capital. While we questioned Deryck about the obvious lack of women in the speakers’ line up, he assured us that Fremantle’s very own Dr Jemma Green was unable to join the event that evening and that visiting Simonne Hurse of Techfest-club.com and Satis group would be among panellists on the night. I really really care about getting more women involved in all this, and I co-run a group for women in tech here in NYC, with 2000 members. We're always looking for excellent speakers + companies to sponsor the group, please get in touch if you'd like to get involved. (http://www.techfest-club.com/) From Simonne’s profile on LinkedIn. Dr Scott Stornetta struck our imagination and Amy-Rose is musing over whether he’s actually Satoshi, or better, Scottoshi… Currently a high-school maths teacher, he started working on the blockchain idea back in 1991 while working as a researcher at Bell Labs, before even the unfolding of the internet. The research involved whether he and a colleague, could make a digital file unbreakable and indelible, according to Deryck. They were unable to prove their hypothesis, but then 3 months later, they couldn’t prove that it COULDN’T be done either… Some time later while queuing at a busy restaurant one Sunday lunch, he had an ‘ahah’ moment when he observed all the people lined up in front and behind him, with the other diners watching them in line… “Hashtags in a chain were the people in the queue, and the distributed ledger were the people watching us in the crowd…” Dr Scott Stornetta’s work is mentioned 3 times in the Bitcoin whitepaper by Satoshi Nakamoto. Deryck has been involved in a number of community charity events, one that saw Perth Porsche drivers take children out for a convoy ride through the streets and city of Perth in conjunction with Make-a-Wish Australia (transforming the lives of children battling life-threatening medical conditions through the healing power of a wish), raising in the meantime hundreds of thousands of dollars. He currently runs Classic Cars & Coffees one Sunday a month at the University of WA, where between 350 to 550 cars are showcased by members who raise funds for charities. We’re thrilled to be attending Blockchain Economy this coming week and will share all the chats and interviews on the Clothesline! Look out for our Facebook page for more instant information and spontaneous ‘Lives’ where we livestream meetings and events as they happen… Find Out More: https://www.blockchaineconomy.com.au/ https://www.linkedin.com/in/w-scott-stornetta-25186120/ https://www.linkedin.com/in/justindombrowski/ https://www.linkedin.com/in/david-yermack-8b440813a/ https://www.makeawish.org.au/

Dr. Kyle Daigle is professionally trained as a Chiropractor. He joined SNA Technologies (Systemic Neural Adaptation) in December 2014 as the President, Chief Medical Officer, and Managing Director for SNA Global. He is the Co-Inventor of a Patent Pending Digital Therapy Software program called Neurosage. Keeping his finger on the pulse of his patients as […] The post Episode 37 – Neurosage: The Video Game that Can Reboot Your Brain! appeared first on Adventures in Brain Injury.

Mike Muhney is living the good life, traveling the country speaking and inspiring thousands of people. As the Cofounder of ACT! CRM Software, and quite literally invented the need for the sales industry, Mike is straight out of Halt and Catch Fire, the TV show. In this episode, we talk about his journey of a few false starts, to building a massive tech company and creating a new industry within the space. So learn from the master, and see what you can apply to your business! To get Mike for your speaking event go to: mikemuhney.com   _____________________________________________ Our Podcast is now on SPOTIFY!! Click Here “The Rebel Way” Reality show COMING SOON RebelCon2018- Coming September 2018 More Podcasts, Videos and Articles of other Rebel Role Models at: www.rebelrolemodel.com Follow Us on Instagram, Facebook, Twitter, Snap, Linked @RebelRoleModel Click here to watch Rebel Role Model TV!  

CRISPR – the new technique to manipulate genes. It's big. And so are the ethical question it raises. CRISPR's co-inventor Jennifer Doudna, a geneticist and an environmental activist on the ethics of this revolutionary technology.

Not many people can claim to have literally created not only an entire software category but as a result also a global multi-billion dollar industry. Mike is one of two guys that did, the other being his past business partner. Together they invented ACT!, the product that is still on the market after 31 years and that created, from nothing, the entire relationship management software category and industry today known as CRM.   Where you can find Mike online: mikemuhney.com Twitter   What did you think of this episode? I want to know. Go to MarkStruczewski.com/muhney and leave a comment.   To leave feedback about the podcast or give suggestions for ideas for future episodes (including guests you'd like to hear me interview), go to MarkStruczewski.com/mypodcast or email feedback@markstruczewski.com. If you are looking to take your productivity to the next level or if you are interested in bringing me in to speak at your event, visit MarkStruczewski.com. Follow me on LinkedIn, Facebook, Twitter and Instagram. Subscribe to my weekly Next Level Productivity Digest. If you love the show, share it with a friend on Apple Podcasts.

Not many people can claim to have literally created not only an entire software category but as a result also a global multi-billion dollar industry. Mike is only one of two guys that did, the other being his past business partner.  Born and raised in Chicago, Mike started his career with IBM in the pre-PC Mainframe era and was classically trained as a Marketing Rep (a fancy way of saying “Sales”) in their 6-month deep-dive intensive Sales Training School of which he graduated 6 out of 66 in his national class. He went on to have a very successful career with IBM who instilled in him many of the principles that he applied later as a software entrepreneur. Mike has experienced both success and failure as an entrepreneur and lives by the credo Dare Greatly! - Fail to Succeed! Audiences find Mike exceptionally, and vulnerably, transparent and authentic that captures their hearts because of his relate-ability and enthuses the human spirit in his audiences to rise above the norm in realizing their greatest potential.  Mike's career has truly been uniquely, irrefutably, and intensely focused on effecting meaningful relationships. As a software entrepreneur he developed world-class tools to enable people to realize and achieve more effective, meaningful, real, and connected relationships in both their business as well as their personal landscape of networks. Mike is best known as the Co-Founder and Co-Inventor of ACT!, the product that literally created the entire Relationship Management software category and global industry and that has been purchased by over 10 million people in the world. Still on the market today after 31 years ACT! has always been acknowledged as the catalyst that created the CRM multi-billion industry.  Mike has spoken to over 250,000 people worldwide as the Keynote Speaker for companies such as Toshiba, Compaq, UT-Dallas, University of Illinois, IDG Publications, the California Professional Women Conference, Singapore Business Expositions, and numerous sales conferences among others as well as speaking on stage with other technology industry titans such as Masayoshi Son, the Founder & CEO of Softbank. Known as The Connection Expert Mike helps people and businesses build substantive and sustainable relationships that enables greater achievement and stronger networks from which all livelihoods depend. Mike can be reached at Mike@MikeMuhney.com. In January 2015 Mike was recognized in a FORBES article as one of the “25 Professional Networking Experts to Watch in 2015” along with such notables as Tim Ferriss and Keith Ferrazzi.  http://www.forbes.com/sites/johncorcoran/2015/01/08/25-professional-networking-experts-to-watch-in-2015/   Topics:  The real “R” in CRM is not about Relationships, but something more important Everybody Sells, making that 1-degree of difference Business is a Contact Sport - Success, Failure and What's Next   Connect with Mike at www.MikeMuhney.com

Jane Och – Guac-Lock “No One Knows About Your Product Like You Do!” Jane Och, co-inventor of Guac-Lock, is a mom on a mission who solved a major party problem: brown guacamole. After some relentless brainstorming, and prototype testing, Jane developed a patent-pending plastic storage system that would keep her ‘guac’ green for days! With a design innovation award granted, a licensing deal created, and some minor snafus solved, Jane shares her energetic story along with a handful of lessons learned in product design. Whether you’re a product manager in an established company or an aspiring business owner with an idea for a new product business, Making It Real will provide you with real tools and advice on how to be a successful product entrepreneur! Hosted by Bob Caporale and Tate Tegtmeier Original Music by Bob Caporale Note: No endorsement of any product or service featured on Making It Real is either expressed or implied by its hosts or producers.

Jane Och – Guac-Lock “No One Knows About Your Product Like You Do!” Jane Och, co-inventor of Guac-Lock, is a mom on a mission who solved a major party problem: brown guacamole. After some relentless brainstorming, and prototype testing, Jane developed a patent-pending plastic storage system that would keep her ‘guac’ green for days! With a design innovation award granted, a licensing deal created, and some minor snafus solved, Jane shares her energetic story along with a handful of lessons learned in product design. Whether you’re a product manager in an established company or an aspiring business owner with an idea for a new product business, Making It Real will provide you with real tools and advice on how to be a successful product entrepreneur! Hosted by Bob Caporale and Tate Tegtmeier Original Music by Bob Caporale Note: No endorsement of any product or service featured on Making It Real is either expressed or implied by its hosts or producers.

An interview with "the father of the Internet” TCP/IP co-inventor Vint Cerf.   Cerf was born June 23, 1943 is an American Internet pioneer, who is recognized as one of "the fathers of the Internet”, sharing this title with TCP/IP co-inventor Bob Kahn. His contributions have been acknowledged and lauded, repeatedly, with honorary degrees and awards that include the National Medal of Technology, the Turing Award, the Presidential Medal of Freedom, the Marconi Prizeand membership in the National Academy of Engineering.   In the early days, Cerf was a manager for the United States' Defense Advanced Research Projects Agency (DARPA) funding various groups to develop TCP/IP technology. When the Internet began to transition to a commercial opportunity during the late 1980s, Cerf moved to MCIwhere he was instrumental in the development of the first commercial email system (MCI Mail) connected to the Internet.   Cerf was instrumental in the funding and formation of ICANN from the start. He waited a year before stepping forward to join the ICANN Board, and eventually became chairman. He was elected as the president of the Association for Computing Machinery in May 2012, and in August 2013 he joined the Council on CyberSecurity's Board of Advisors.   Cerf is active in many organizations that are working to help the Internet deliver humanitarian value to the world. He is supportive of innovative projects that are experimenting with new approaches to global problems, including the digital divide, the gender gap, and the changing nature of jobs. Cerf is also known for his sartorial style, typically appearing in a three-piece suit—a rarity in an industry known for its casual dress norms.   More here - https://en.wikipedia.org/wiki/Vint_Cerf

We hear about bad times when companies fail (though maybe not enough).  But what does it look like when massive success wreaks havoc on your life? Mike Muhney is on the show today.  He is the Co-Founder and Co-Inventor of ACT! software - the first CRM.  Customer Relationship software is a multi-billion dollar industry that was born from ACT!. We find out firsthand how ACT! came to be and how what started it all is at the core of everything Mike does, including his new venture that's about to launch.

Visit EOFire.com for complete show notes of every Podcast episode. Mike is the CEO of VIPorbit Software. Its Vipor Family of products providing solutions for relationship, activity and collaboration management for Apple users is best known as the Co-Inventor of ACT!, the product that literally created the entire relationship management software category and global industry. His vision with Vipor is to go beyond the success of ACT! and once again change the world.

This amazing story chronicles Mike Muhney's journey from a $100,000 angel investment to selling the first CRM (Customer Relationship Management) software for 40 Million Dollars. Packed with important business lessons Mike gleaned from being a sales person at IBM to negotiating strategies, the importance of relationships, and the value of following your dreams, this 3 times the normal length episode takes you on a fascinating ride from a great storyteller.  Get A Company of Owners, Beached Whale, Whiteboard, and The Sink here: http://goo.gl/zggRqd   www.DarenMartin.com  http://viporbit.com/ https://www.amazon.com/Whos-Your-Orbit-Facebook-Relationships/dp/0983041504/ref=sr_1_1?ie=UTF8&qid=1496598079&sr=8-1&keywords=mike+muhney

In our pilot episode of The Webby Podcast, Webby Awards Executive Director David-Michel Davies sits down with the Co-Inventor of the Internet and Chief Internet Evangelist for Google, Vint Cerf. They talk about the early days of computing, Al Gore, and security concerns in 2017.Follow us everywhere @ TheWebbyAwardsand keep up with David-Michel @ dmdlikesProducer: Ben WagnerEditorial Supervisor: Nicole FerraroMusic: "Straight West" by Kasket Club, courtesy of Audiosocket Hosted on Acast. See acast.com/privacy for more information.

Segment 1: Brayden Olson has been recognized by Fortune Magazine as one of five “Startup Idols”. Huffington Post also ranked his work between the iPad and Gmail as one of the most important Innovations of the year and this was the year after Olson graduated from university. He is CEO and Co-Inventor of Recurrence Inc, a software company on the cutting edge of gamification. Segment 2: Jessica Mah is the Founder and CEO of inDinero, which helps entrepreneurs with all their accounting and tax needs. Segment 3: Doren Aldana is the CEO and President of the Testimonial Engine, a software for helping service-based businesses collect and share client reviews on autopilot. Segment 4: Julia Hutton launched Orca Communications in 2002 after a 40-year career in various facets of corporate public relations. Segment 5: Desiree Young is the founder of VentureWalk, a forward-thinking business and entrepreneur development firm.  Sponsored by Nextiva and Sage Summit.

Mike is the CEO of VIPorbit Software. Its Vipor Family of products providing solutions for relationship, activity and collaboration management for Apple users is best known as the Co-Inventor of ACT!, the product that literally created the entire relationship management software category and global industry. His vision with Vipor is to go beyond the success of ACT! and once again change the world. Visit EOFire.com

Bios Incube is the world´s first system designed to help grow the remains of your loved ones into trees.